[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 964
1. Stewart CJ, Brennan BA, Hammond IG, Leung YC, McCartney AJ, Ruba S: Intraoperative assessment of clear cell carcinoma of the ovary. Int J Gynecol Pathol; 2008 Oct;27(4):475-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative assessment of clear cell carcinoma of the ovary.
  • Our impression that primary clear cell carcinoma (CCC) causes disproportionate diagnostic difficulty led us to review the intraoperative and final histopathologic reports from a consecutive series of 44 CCC that were subject to frozen-section assessment and to compare the results with a similar number of primary serous and endometrioid carcinomas.
  • Review of the diagnostic reports showed that CCC was less frequently specifically identified than serous or endometrioid carcinomas on frozen section (44% cases compared with 55% and 65%, respectively), although the differences were not statistically significant.
  • Difficulties in distinguishing primary ovarian carcinoma from tumors metastatic to the ovary occurred in a minority of cases of all histologic subtypes, but was slightly more frequent in CCC.
  • Review of the frozen-section slides from the CCC with discrepant intraoperative diagnoses showed features suggestive or indicative of the correct diagnosis in 7 (39%) of 18 cases.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cystadenocarcinoma, Serous / pathology. Cystadenoma, Serous / pathology. Female. Frozen Sections. Histocytochemistry. Humans. Intraoperative Care / methods. Pathology, Surgical. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753976.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Testa D, Galli V, de Rosa G, Iovine R, Staibano S, Somma P, Mignogna C, Iengo M: Clinical and prognostic aspects of laryngeal clear cell carcinoma. J Laryngol Otol; 2005 Dec;119(12):991-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and prognostic aspects of laryngeal clear cell carcinoma.
  • Clear cell carcinoma (CCC) of the larynx is a rare pathological finding; only eight cases are described in the literature.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Laryngeal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354366.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 18
  •  go-up   go-down


3. Ivanov SV, Ivanova AV, Salnikow K, Timofeeva O, Subramaniam M, Lerman MI: Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. Biochem Biophys Res Commun; 2008 Jun 13;370(4):536-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors.
  • The inability of the mutant VHL protein to destabilize HIF-1 plays a crucial role in malignant angiogenesis.
  • We used expression arrays and cell lines with different VHL status to identify ECM-associated genes controlled by VHL.
  • Analyzing the mechanism of TGFBI up-regulation in clear cell carcinoma, we identified a novel VHL target, a Kruppel-like transcriptional factor 10 (KLF10).

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2001 Feb;21(3):865-74 [11154273.001]
  • [Cites] Exp Biol Med (Maywood). 2007 Mar;232(3):344-52 [17327467.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15306-15 [11278694.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4184-9 [11358843.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):6996-7001 [11585723.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2848-53 [11880636.001]
  • [Cites] Jpn J Clin Oncol. 2002 Mar;32(3):85-9 [11956302.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2929-36 [12019174.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3803-11 [12097293.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):28003-9 [12034705.001]
  • [Cites] Oncogene. 2002 Aug 22;21(37):5783-90 [12173049.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):673-82 [12209156.001]
  • [Cites] Gynecol Oncol. 2007 Sep;106(3):461-8 [17624412.001]
  • [Cites] J Cell Biochem. 2007 Oct 15;102(3):539-48 [17729309.001]
  • [Cites] J Pathol. 2008 Jan;214(1):46-57 [17973242.001]
  • [Cites] Biochim Biophys Acta. 2002 Oct 9;1588(1):1-6 [12379307.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46159-65 [12270930.001]
  • [Cites] Neurosci Lett. 2003 Jan 16;336(2):93-6 [12499048.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):213-26 [12510773.001]
  • [Cites] Int J Oncol. 2003 Mar;22(3):551-60 [12579308.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):2045-53 [12673209.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Jul;44(7):2973-9 [12824240.001]
  • [Cites] FEBS Lett. 2004 Jan 2;556(1-3):137-42 [14706840.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1235-43 [15026807.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Apr 15;196(2):258-65 [15081272.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 25;101(21):8132-7 [15141079.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):26948-58 [15087465.001]
  • [Cites] Exp Mol Med. 2004 Jun 30;36(3):211-9 [15272232.001]
  • [Cites] DNA Cell Biol. 1992 Sep;11(7):511-22 [1388724.001]
  • [Cites] Nucleic Acids Res. 1995 Dec 11;23(23):4907-12 [8532536.001]
  • [Cites] Biochim Biophys Acta. 1998 Feb 11;1395(3):288-92 [9512662.001]
  • [Cites] J Biol Chem. 1998 Oct 2;273(40):25929-36 [9748269.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12596-601 [9770531.001]
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] Mol Cell Biol. 1999 Sep;19(9):5902-12 [10454537.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4440-5 [10485495.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):97-101 [15661539.001]
  • [Cites] Mol Carcinog. 2006 Feb;45(2):84-92 [16329146.001]
  • [Cites] Am J Pathol. 2006 Feb;168(2):574-84 [16436671.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2818-26 [16314830.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5314-21 [16707457.001]
  • [Cites] Hum Mutat. 2006 Jul;27(7):615-25 [16683255.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6928-35 [16849536.001]
  • [Cites] Oncogene. 2007 Feb 8;26(6):802-12 [16878149.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • (PMID = 18359287.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 BC008579-14; United States / NCI NIH HHS / CO / N01-CO-56000
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Early Growth Response Transcription Factors; 0 / Extracellular Matrix Proteins; 0 / KLF10 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Transforming Growth Factor beta; 148710-76-3 / betaIG-H3 protein; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  • [Other-IDs] NLM/ NIHMS51643; NLM/ PMC2413015
  •  go-up   go-down


Advertisement
4. Tillou X, Demailly M, Hakami F, Westeel PF, Saint F, Petit J: De novo renal carcinoma in renal transplant recipients: effect of early treatment. Transplant Proc; 2009 Oct;41(8):3314-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo renal carcinoma in renal transplant recipients: effect of early treatment.
  • OBJECTIVE: To evaluate the epidemiology, diagnosis, and outcome of de novo renal cell carcinoma in renal transplant recipients.
  • Incidence, diagnosis, histologic type, treatment, and outcome were analyzed in all patients.
  • RESULTS: Thirty-three patients underwent nephrectomy because of suspect renal lesions including 22 de novo tumors in 21 native kidneys (renal clear-cell carcinoma in 15 and papillary carcinoma in 7).
  • Mean (range) time after diagnosis was 25.6 (2.3-105.5) months.
  • Only 1 patient died, at 8 months after diagnosis.
  • In our patients, 65% of patients had malignant lesions.
  • [MeSH-major] Carcinoma, Renal Cell / epidemiology. Kidney Neoplasms / epidemiology. Kidney Transplantation / adverse effects
  • [MeSH-minor] Abdomen / ultrasonography. Adult. Aged. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Humans. Incidence. Middle Aged. Nephrectomy. Prognosis. Retrospective Studies. Risk Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19857739.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Hartmann A, Junker K, Dietmaier W, Schröder S, Lopez D, Hofstädter F, Blaszyk H: Molecular evidence for progression of nephrogenic metaplasia of the urinary bladder to clear cell adenocarcinoma. Hum Pathol; 2006 Jan;37(1):117-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular evidence for progression of nephrogenic metaplasia of the urinary bladder to clear cell adenocarcinoma.
  • Previous case reports suggest the possibility of nephrogenic metaplasia progressing to clear cell adenocarcinoma, but a malignant potential of nephrogenic metaplasia is generally not acknowledged.
  • A case of a 70-year-old female patient with multiple recurrences of nephrogenic metaplasia of the urinary bladder and subsequent development of clear cell adenocarcinoma is described.
  • Results of molecular studies, particularly comparative genomic hybridization analysis, suggest clonal evolution of nephrogenic metaplasia to clear cell adenocarcinoma in this case.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenoma / pathology. Precancerous Conditions / pathology. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Clone Cells. Cystectomy. DNA, Neoplasm / analysis. Disease Progression. Disease-Free Survival. Female. Humans. Loss of Heterozygosity. Metaplasia / genetics. Metaplasia / metabolism. Metaplasia / pathology. Neoplasm Recurrence, Local. Nucleic Acid Hybridization. Urethra / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360424.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


6. Thompson RH, Dong H, Kwon ED: Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res; 2007 Jan 15;13(2 Pt 2):709s-715s
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy.
  • B7-H1 encompasses a recently discovered cell surface glycoprotein within the B7 family of T-cell co-regulatory molecules.
  • Tumor-associated B7-H1, as well as B7-H1 on activated lymphocytes, has been shown to impair antigen-specific T-cell function and survival in vitro.
  • Our group has recently reported that B7-H1 is aberrantly expressed in both primary and metastatic renal cell carcinoma (RCC) as revealed via immunohistochemical staining of both fresh-frozen and paraffin-embedded nephrectomy specimens.
  • In addition, we have shown that B7-H1 expression by clear cell RCC tumors (or infiltrating mononuclear cells) correlates with aggressive pathologic features, including advanced tumor-node-metastasis stage, tumor size, higher nuclear grade, and coagulative necrosis.
  • In one study of 306 patients, with a median clinical follow-up of 11 years, we reported that RCC B7-H1 expression correlates with increased risk of disease progression, cancer-specific death, and overall mortality even after multivariate adjustment.
  • Such associations may relate to the recognized ability of B7-H1 to inhibit T-cell-mediated antitumoral immunity.
  • [MeSH-minor] Animals. Antigens, CD274. Antigens, Neoplasm / metabolism. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Disease Models, Animal. Humans. Immunotherapy / methods. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology. Mice. Neoplasm Metastasis. Prognosis. T-Lymphocytes / metabolism. Time Factors

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255298.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / Antigens, Neoplasm; 0 / CD274 protein, human
  • [Number-of-references] 42
  •  go-up   go-down


7. Seko A, Kataoka F, Aoki D, Sakamoto M, Nakamura T, Hatae M, Yonezawa S, Yamashita K: N-Acetylglucosamine 6-O-sulfotransferase-2 as a tumor marker for uterine cervical and corpus cancer. Glycoconj J; 2009 Nov;26(8):1065-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • N-Acetylglucosamine 6-O-sulfotransferase-2 (GlcNAc6ST2) is ectopically expressed in ovarian mucinous and clear cell adenocarcinoma [Kanoh et al., Glycoconj J 23:453-460, 2006].


8. Komiyama S, Nakamura M, Murakami I, Kuwabara Y, Kurahashi T, Tanaka K, Mikami M: A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine. Arch Gynecol Obstet; 2008 Dec;278(6):565-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine.
  • INTRODUCTION: Advanced clear cell adenocarcinoma of the ovary is a histologic type with an extremely poor prognosis.
  • No reports have been published concerning useful drugs for salvage chemotherapy for this type of cancer.
  • We performed salvage therapy with gemcitabine in a patient with multiple-drug- resistant, unresectable recurrent clear cell adenocarcinoma of the ovary and succeeded in stabilizing recurrent lesions and controlling carcinomatous peritonitis.
  • CASE REPORT: A 55-year-old woman was in Stage IIIc of clear cell adenocarcinoma of the ovary.
  • After three courses of fourth-line chemotherapy with gemcitabine for the treatment of carcinomatous peritonitis and hepatic and splenic metastatic lesions, serum CA-125 and the severity of ascites showed marked decreases, and its efficacy for the hepatic and splenic metastatic lesions was classified as 5-month stable disease.
  • CONCLUSION: Gemcitabine is also useful for heavily pretreated clear cell adenocarcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Peritonitis / drug therapy. Salvage Therapy / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Gynecol Obstet. 2009 Feb;279(2):271. Komiyama, Shin [corrected to Komiyama, Shin-ichi]
  • (PMID = 17576588.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


9. Fadare O, Liang SX, Ulukus EC, Chambers SK, Zheng W: Precursors of endometrial clear cell carcinoma. Am J Surg Pathol; 2006 Dec;30(12):1519-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursors of endometrial clear cell carcinoma.
  • In contrast to uterine endometrioid and serous carcinomas, very little is known about the potential precursor lesions of endometrial clear cell carcinoma (ECCC).
  • In our routine practice, we have noted the presence of a spectrum of atypical glandular changes in the endometria adjacent to ECCC or endometrial carcinomas with a clear cell component, which on the basis of current criteria, would not qualify for any specific designation.
  • Thirty archived cases of pure ECCC (n=14) or mixed endometrial carcinomas with a >10% clear cell component (n=16) were retrieved and the "normal" endometria adjacent to the malignancies were evaluated in detail.
  • Thirty-eight benign uteri and 30 uteri with classic endometrial endometrioid carcinoma (EEC) served as controls.
  • In contrast, PPL were identified neither in the benign uteri nor in endometrioid carcinoma control groups (P<0.001).
  • ER/progesterone receptor indices for benign endometria, PPL, and carcinoma were 90/80, 21.52/4.61, and 11/4, respectively.
  • The PPL described herein have a morphologic and immunophenotypic profile which seems to be distinct from both the benign endometria in which they reside and the adjacent areas of ECCC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometrial Neoplasms / pathology. Precancerous Conditions / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122507.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


10. Yokota N, Koizume S, Miyagi E, Hirahara F, Nakamura Y, Kikuchi K, Ruf W, Sakuma Y, Tsuchiya E, Miyagi Y: Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer; 2009 Dec 15;101(12):2023-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Ectopic fVII expression occurs frequently in ovarian cancers, particularly in clear cell carcinoma.
  • We further showed that ovarian cancer cells express TF-fVIIa on the cell surface under normoxia and that this procoagulant activity is enhanced by hypoxic stimuli.
  • CONCLUSION: These results raise the possibility that cancer cell-derived TF-fVIIa could cause thrombotic events in ovarian cancer patients.
  • [MeSH-minor] Cell Hypoxia. Cell Line, Tumor. Cell-Derived Microparticles / secretion. Female. Humans. Neoplasms, Glandular and Epithelial / chemistry

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thromb Res. 2007;120 Suppl 2:S7-12 [18023716.001]
  • [Cites] Br J Cancer. 2007 Oct 22;97(8):1053-7 [17895896.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jun 27;371(2):251-5 [18423372.001]
  • [Cites] Nat Rev Cancer. 2008 Jun;8(6):425-37 [18500244.001]
  • [Cites] J Thromb Haemost. 2008 Sep;6(9):1517-24 [18433463.001]
  • [Cites] Pathophysiol Haemost Thromb. 2008;36(3-4):177-83 [19176990.001]
  • [Cites] Cell. 1988 May 20;53(4):505-18 [3286010.001]
  • [Cites] Am J Pathol. 1996 May;148(5):1567-76 [8623925.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8298-303 [9653181.001]
  • [Cites] Thromb Haemost. 1998 Oct;80(4):598-602 [9798977.001]
  • [Cites] J Thromb Haemost. 2004 Nov;2(11):2065-7 [15550054.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1406-13 [15735028.001]
  • [Cites] J Thromb Haemost. 2005 Aug;3(8):1737-44 [16102040.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):119-25 [15990161.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):755-61 [16380413.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7067-74 [16849552.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7983-90 [16912173.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9453-60 [17018600.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):70-6 [17194906.001]
  • [Cites] Thromb Haemost. 2007 Jan;97(1):119-23 [17200778.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):290-5 [17211468.001]
  • [Cites] J Thromb Haemost. 2007 Mar;5(3):520-7 [17166244.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):480-7 [10690527.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2870-5 [17504985.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):784-90 [17408726.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1723-9 [17496204.001]
  • [Cites] J Thromb Haemost. 2008 May;6(5):781-8 [18284604.001]
  • (PMID = 19904262.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL060742
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9001-25-6 / Factor VII; 9035-58-9 / Thromboplastin
  • [Other-IDs] NLM/ PMC2795428
  •  go-up   go-down


11. Pouessel D, Culine S: Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel. Expert Rev Anticancer Ther; 2006 Dec;6(12):1761-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
  • The year 2006 will mark a turning point in the daily management of patients with metastatic renal cell carcinoma.
  • The growing understanding of molecular mechanisms involved in the pathogenesis of the disease, especially clear-cell carcinoma, has led to the development of multiple targeted therapies with significant clinical benefits.
  • Further studies are needed to determine the optimal combinations of these agents in metastatic disease and to assess their impact in the adjuvant setting.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17181490.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Immunologic Factors; 0 / Indoles; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Neoplasm Proteins; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 2S9ZZM9Q9V / Bevacizumab; 624KN6GM2T / temsirolimus; 9ZOQ3TZI87 / sorafenib; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; W36ZG6FT64 / Sirolimus
  • [Number-of-references] 42
  •  go-up   go-down


12. Stolnicu S, Borda A, Radulescu D, Puscasiu L, Berger N, Nogales FF: Metastasis from papillary renal cell carcinoma masquerading as primary ovarian clear cell tumor. Pathol Res Pract; 2007;203(11):819-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis from papillary renal cell carcinoma masquerading as primary ovarian clear cell tumor.
  • Microscopic examination disclosed cystic spaces lined by abundant clear and eosinophilic tumor cells with pleomorphic nuclei.
  • Differential diagnosis included primary ovarian oxyphilic-type clear cell carcinoma and sex-cord tumor with extensive luteinization.
  • However, analysis of the patient's past history revealed that in 2003, she had undergone nephrectomy for a papillary renal cell carcinoma, and a histological comparison between the primary and the present tumor exhibited in the latter a substantially larger number of clear cells and loss of papillary architecture.
  • Immunohistochemistry demonstrated a characteristic renal immunophenotype for a type II tubulopapillary tumor metastatic to ovary.
  • This is the first reported case of ovarian metastases of type II tubulopapillary carcinoma of the kidney.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neprilysin / metabolism. Racemases and Epimerases / metabolism


13. Lee S, Garner EI, Welch WR, Berkowitz RS, Mok SC: Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol; 2007 Aug;106(2):311-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma.
  • OBJECTIVE: Unlike other histological types of epithelial ovarian carcinoma, ovarian clear cell carcinoma is known to have very poor response to therapy even when discovered in its early stages.
  • Since tumor hypoxia has been shown to be strongly associated with poor prognosis, deregulation of the representative factor of tissue hypoxia; hypoxia-inducible factor 1 alpha (HIF-1alpha) and related protein; Von Hippel-Lindau (VHL) may be associated with poor prognosis of ovarian clear cell carcinoma.
  • METHODS: Immunolocalization of both HIF-1alpha and VHL was performed on 56 cases of paraffin-embedded tissue sections of four different histological types of epithelial ovarian carcinoma and 5 cases of benign ovarian tumors as a control.
  • Quantitative RT-PCR analysis of both HIF1A and VHL was performed on RNA isolated from 61 microdissected frozen tissues of four different histological types of epithelial ovarian carcinoma and 6 cases of normal ovarian epithelial cells.
  • RESULTS: HIF-1alpha expression levels were significantly higher in ovarian clear cell carcinoma than in other histological types (P=0.001).
  • We found no correlation between mRNA and protein expression level in any type of carcinoma specimens.
  • Among endometrioid, serous, and mucinous carcinoma, there were no differences in HIF-1alpha expression (P=0.643).
  • There was a negative correlation between HIF-1alpha and VHL in serous (r=-0.661, P=0.027) and in endometrioid carcinoma (r=-0.657 P=0.039), but no correlation was found between HIF-1alpha and VHL expression levels in ovarian clear cell carcinoma (P=0.60).
  • CONCLUSIONS: The results suggest that the role of hypoxia may change according to the histological type of ovarian carcinoma.
  • High expression of HIF-1alpha and its independence from VHL in ovarian clear cell carcinoma may confer chemoresistance in this histological type.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Med Hypotheses. 2006;66(2):380-3 [16229963.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):411-21 [10934146.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1830-2 [11280732.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] Biochem J. 2002 Feb 15;362(Pt 1):71-9 [11829741.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1573-81 [12627523.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):176-81 [12673675.001]
  • [Cites] Cancer Treat Rev. 2003 Aug;29(4):297-307 [12927570.001]
  • [Cites] Cancer. 1977 Dec;40(6):3019-29 [589565.001]
  • [Cites] CA Cancer J Clin. 1980 Jan-Feb;30(1):2-15 [6766347.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):199-203 [2807010.001]
  • [Cites] Gynecol Oncol. 1993 Nov;51(2):141-9 [8276286.001]
  • [Cites] Nat Genet. 1994 May;7(1):85-90 [7915601.001]
  • [Cites] Hum Mol Genet. 1994 Dec;3(12):2169-73 [7881415.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 [7539918.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):412-7 [8774649.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2157-63 [8918409.001]
  • [Cites] Kidney Int. 1997 Feb;51(2):560-3 [9027739.001]
  • [Cites] Nature. 1998 Jul 30;394(6692):485-90 [9697772.001]
  • [Cites] Gynecol Oncol. 1998 Aug;70(2):255-8 [9740700.001]
  • [Cites] EMBO J. 1998 Nov 16;17(22):6573-86 [9822602.001]
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1973-81 [16123149.001]
  • [Cites] Sci STKE. 2005 Oct 18;2005(306):re12 [16234508.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):343-7 [16051334.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • (PMID = 17532031.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R33 CA103595; United States / NCI NIH HHS / CA / R33 CA103595-04; United States / NCI NIH HHS / CA / CA103595-04; United States / NCI NIH HHS / CA / CA105009-030002; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / P50 CA105009-030002; United States / PHS HHS / / P50105009; United States / NCI NIH HHS / CA / R01 CA133057; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  • [Other-IDs] NLM/ NIHMS28316; NLM/ PMC1995602
  •  go-up   go-down


14. Kinoshita T, Inoue H, Kinouchi T, Kobayashi M, Takada T, Hara T, Hatano K, Nonomura N: Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report. Int J Urol; 2010 Mar;17(3):286-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report.
  • We present the case of a patient with renal cell carcinoma treated preoperatively with sorafenib.
  • Complete resection of the left renal mass measuring 7.2 x 6.6 cm seemed to be difficult at diagnosis because of large renal hilar lymph nodes.
  • Pathological findings revealed that over 90% of the renal tumor was substituted by necrotic fibrotic tissue and that the residual neoplastic component was diagnosed as clear cell carcinoma.
  • At 6 months after radical nephrectomy, a new computed tomography scan revealed no evidence of disease with the disappearance of lung nodules.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Benzenesulfonates / administration & dosage. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery. Pyridines / administration & dosage

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20409221.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


15. Castellvi J, Garcia A, de la Torre J, Hernandez J, Gil A, Xercavins J, Ramón y Cajal S: Ephrin B expression in epithelial ovarian neoplasms correlates with tumor differentiation and angiogenesis. Hum Pathol; 2006 Jul;37(7):883-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differential gene expression studies are identifying new sets of genes with a role in the classification, differential diagnosis, and prognosis of some human tumors.
  • Ephrin B1, a factor involved in angiogenesis, has been shown to be up-regulated in ovarian carcinomas, making it a potential target for cancer treatment.
  • Specimens from 112 benign, borderline, and malignant epithelial ovarian tumors were examined.
  • Ephrin B was detected in 50% of ovarian tumors: clear cell carcinomas (93%), serous carcinomas (74%), mucinous carcinomas (29%), and endometrioid carcinomas (27%).
  • High-grade carcinomas showed greatest ephrin B expression, whereas benign tumors and low-grade carcinomas were rarely positive.
  • A correlation was found between ephrin B expression and microvessel density, supporting the angiogenic role of this factor in ovarian carcinomas.
  • Ephrin B expression was associated with higher rates of disease recurrence and a decrease in overall survival.
  • A distinctive pattern of ephrin B expression was observed in ovarian tumors: high-grade tumors and clear cell and serous carcinomas show higher expression, correlating with the aggressiveness.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Differentiation. Female. Humans. Immunohistochemistry. Microcirculation. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784989.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ephrin-B1
  •  go-up   go-down


16. Veras E, Mao TL, Ayhan A, Ueda S, Lai H, Hayran M, Shih IeM, Kurman RJ: Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol; 2009 Jun;33(6):844-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases.
  • Ovarian clear cell carcinomas (CCC) typically present as large adnexal, stage I tumors and are generally considered highly malignant.
  • They are frequently associated with endometriosis and, less often with clear cell adenofibromas.
  • Various features were analyzed including: age, race, laterality, tumor size, architectural pattern (papillary, tubulo-cystic, solid, mixed patterns), grade, mitotic index, association with endometriosis including atypical endometriosis/intraepithelial carcinoma, stage and survival.
  • Both the cystic and adenofibromatous CCC forms were associated with endometriosis and atypical endometriosis/intraepithelial carcinoma, but the frequency was much higher in the cystic group.
  • Specifically, endometriosis was found in 91% of cystic CCCs and atypical endometriosis/intraepithelial carcinoma in 62% of these cases, whereas endometriosis was found in 44% of adenofibromatous CCCs and atypical endometriosis/intraepithelial carcinoma in 11% of cases.
  • A predominantly papillary pattern was seen in 47% of cystic CCCs, whereas none of the adenofibromatous carcinomas displayed a predominantly papillary pattern.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenofibroma / pathology. Cysts / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19342944.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Rotellini M, Fondi C, Paglierani M, Stomaci N, Raspollini MR: Clear cell carcinoma of the bladder in a patient with a earlier clear cell renal cell carcinoma: a case report with morphologic, immunohistochemical, and cytogenetical analysis. Appl Immunohistochem Mol Morphol; 2010 Jul;18(4):396-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the bladder in a patient with a earlier clear cell renal cell carcinoma: a case report with morphologic, immunohistochemical, and cytogenetical analysis.
  • Clear cell transitional carcinoma of the bladder is a subtype of transitional carcinoma that morphologically resembles a clear cell renal cell carcinoma.
  • Although kidney tumors do not frequently metastasize to the bladder, the recurrence after a clear cell renal cell carcinoma has been reported even several years after nephrectomy.
  • We report the case of a male patient to whom radical nephrectomy for a clear cell renal cell carcinoma has been done, with a bladder tumor featuring polygonal cells with abundant clear cytoplasm deeply infiltrating the vesical wall.
  • We discuss the morphologic features, the immunohistochemical staining with a new marker and the UroVysion FISH analysis to achieve a definitive diagnosis.

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216403.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


18. Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Kikuchi Y: Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Int J Clin Oncol; 2007 Aug;12(4):256-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
  • BACKGROUND: Irinotecan hydrochloride, a topoisomerase I inhibitor, has been preliminarily recognized as an effective agent against clear cell carcinoma of the ovary (CCC), but there are few clinical data.
  • METHODS: One hundred and seventeen patients at International Federation of Gynecology and Obstetrics (FIGO) stages Ic (ascites/malignant washing) - IV were identified by scanning the medical records of ten Japanese hospitals.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carboplatin / therapeutic use. Cisplatin / therapeutic use. Ovarian Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):52-6 [16445610.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):723-8 [12079522.001]
  • [Cites] Cancer Lett. 1998 Jun 19;128(2):211-8 [9683285.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):735-40 [14675308.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6880-8 [16203778.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):197-203 [15262142.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2503-12 [14633622.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):412-7 [8774649.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1369-74 [16641903.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):604-10 [1537625.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):893-7 [15894369.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):394-9 [12648592.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):285-91 [16516283.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2584-9 [10861437.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2157-63 [8918409.001]
  • [Cites] Jpn J Clin Oncol. 1999 Sep;29(9):434-7 [10563197.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):327-31 [10671681.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):789-93 [8631015.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1138-50 [1904477.001]
  • [Cites] Jpn J Cancer Res. 1994 Sep;85(9):966-71 [7961127.001]
  • [Cites] Gynecol Oncol. 1993 May;49(2):250-4 [8504995.001]
  • (PMID = 17701003.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0H43101T0J / irinotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


19. Yetkin G, Uludağ M, Ozağari A: Solitary colonic metastasis of renal cell carcinoma. Acta Chir Belg; 2008 Mar-Apr;108(2):264-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary colonic metastasis of renal cell carcinoma.
  • We report a rare case of a solitary metastasis of a renal cell carcinoma which manifested as a primary colonic tumour.
  • A 60-year-old male patient who had undergone a right radical nephrectomy 5 years previously for renal cell carcinoma, presented with a history of dyspepsia and pain in the right upper abdomen.
  • Postoperative histological examination revealed that the tumour was a metastatic renal cell carcinoma of the clear cell type.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Colonic Neoplasms / secondary. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18557158.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


20. Picken MM: The evolving concept of renal neoplasia: impact of emerging molecular and electron microscopic studies. Ultrastruct Pathol; 2005 May-Aug;29(3-4):277-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The classification of renal tumors has evolved from one that initially encompassed only 2 types of tumors, i.e., clear and granular cell carcinomas, to the markedly expanded recent classification that incorporates new entities, some of which are primarily defined by specific molecular abnormalities.
  • Despite these advances, a single tumor category, clear cell carcinoma, still incorporates the majority (approximately 70%) of renal tumors.
  • Electron microscopic studies have been pivotal in defining the spectrum of oncocytoma-chromophobe renal cell carcinoma.
  • Cytoplasmic eosinophilia found in some renal cell carcinomas currently classified as clear cell type is under intense study.
  • Tumors that have recently emerged from this group include tumors with translocations involving chromosome Xp11.2, carcinomas associated with neuroblastoma and epithelioid angiomyolipoma.
  • The author concludes that although the routine application of electron microscopy to kidney tumor diagnosis may not be practical, systematic ultrastructural studies of these tumors may aid in the definition of new entities.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16036881.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


21. Tamada Y, Takeuchi H, Suzuki N, Susumu N, Aoki D, Irimura T: Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary. Cancer Sci; 2007 Oct;98(10):1586-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary.
  • A monoclonal antibody (mAb) MY.1E12 was applied to detect MUC1 with sialylated glycans in a total of 55 formalin-fixed, paraffin-embedded surgical specimens of ovarian clear cell adenocarcinomas.
  • To examine the role of MUC1 in ovarian clear cell carcinomas, two cDNA encoding MUC1 were transfected into ES-2 ovarian clear cell carcinoma cells.
  • The results indicate that MUC1 expressed on ovarian clear cell carcinoma cells is causally involved in the malignant behavior.
  • [MeSH-major] Adenocarcinoma, Clear Cell / immunology. Antibodies, Monoclonal. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mucin-1 / immunology. Ovarian Neoplasms / immunology. Sialic Acids / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17711507.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Mucin-1; 0 / Sialic Acids; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Shih CM, Huang CT, Chi CH, Lin JW, Pan CC: CA125-producing clear cell adenocarcinoma arising from the upper ureter and renal pelvis. J Chin Med Assoc; 2010 Jan;73(1):40-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CA125-producing clear cell adenocarcinoma arising from the upper ureter and renal pelvis.
  • Clear cell adenocarcinomas similar to those found in the female genital organs can arise in the lower urinary tract of both women and men.
  • Clear cell adenocarcinomas occurring in the upper urinary system are exceedingly rare.
  • Here, we present a case of clear cell adenocarcinoma arising from the upper ureter and renal pelvis of a postmenopausal woman with a ureteral stone.
  • The tumor showed typical features of tubulopapillary structures lined with clear-to-eosinophilic cytoplasm and frequent hobnail configuration.
  • Given the presence of intestinal and squamous metaplasia of the adjacent urothelium, we propose that this clear cell adenocarcinoma developed through a metaplastic process.
  • The tumor behaved so aggressively that the patient developed multiple metastases and died of the disease 5 months after radical nephroureterectomy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. CA-125 Antigen / blood. Kidney Neoplasms / pathology. Kidney Pelvis / pathology. Ureteral Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20103490.001).
  • [ISSN] 1728-7731
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / CA-19-9 Antigen
  •  go-up   go-down


23. Verine J, Lehmann-Che J, Soliman H, Feugeas JP, Vidal JS, Mongiat-Artus P, Belhadj S, Philippe J, Lesage M, Wittmer E, Chanel S, Couvelard A, Ferlicot S, Rioux-Leclercq N, Vignaud JM, Janin A, Germain S: Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma. PLoS One; 2010;5(4):e10421
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma.
  • BACKGROUND: We have previously shown that angiopoietin-like 4 (angptl4) mRNA, a hypoxia-inducible gene, is highly expressed in clear cell renal-cell carcinoma (ccRCC), the most common subtype of RCC for which no specific marker is available.
  • In contrast, angptl4 mRNA was neither expressed in 94% non-ccRCC renal tumors (papillary RCCs (n = 46), chromophobe RCCs (n = 28), and oncocytomas (n = 9)), nor in non-renal clear cell carcinomas (n = 39).
  • Angptl4 expression was also examined in tumors associated (n = 23) or not associated (n = 66) with VHL disease.
  • CONCLUSIONS/SIGNIFICANCE: Angptl4 mRNA expression was highly associated with ccRCC (p = 1.5 10(-49), Chi square test) allowing to define its expression as a diagnosis marker for primary ccRCC.
  • Moreover, angptl4 mRNA allows to discriminate the renal origin of metastases of clear-cell carcinomas arising from various organs.
  • [MeSH-major] Angiopoietins / genetics. Carcinoma, Renal Cell / diagnosis. Molecular Diagnostic Techniques. RNA, Messenger / analysis
  • [MeSH-minor] Biomarkers. Diagnosis, Differential. Humans. In Situ Hybridization. Neoplasm Metastasis. RNA, Neoplasm / analysis. Retrospective Studies

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9754-9 [11493696.001]
  • [Cites] Hum Pathol. 2009 Dec;40(12):1671-8 [19695674.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1521-8 [12707035.001]
  • [Cites] Histopathology. 2004 Nov;45(5):452-9 [15500648.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] Nat Genet. 1994 May;7(1):85-90 [7915601.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2477-90 [16339096.001]
  • [Cites] PLoS Med. 2006 Jan;3(1):e13 [16318415.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):51-68 [16512599.001]
  • [Cites] Actas Urol Esp. 2006 Mar;30(3):281-6 [16749584.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18721-6 [17130448.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Lancet Oncol. 2007 Jun;8(6):554-8 [17540307.001]
  • [Cites] Annu Rev Pathol. 2007;2:145-73 [18039096.001]
  • [Cites] Histopathology. 2008 Jan;52(2):158-66 [18036175.001]
  • [Cites] Cell. 2008 Apr 4;133(1):66-77 [18394990.001]
  • [Cites] Biochem Soc Trans. 2008 Jun;36(Pt 3):472-8 [18481984.001]
  • [Cites] Am J Surg Pathol. 2008 Jul;32(7):1051-9 [18496143.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4726-34 [18676741.001]
  • [Cites] Am J Surg Pathol. 2008 Oct;32(10):1462-7 [18685487.001]
  • [Cites] Nat Rev Cancer. 2008 Nov;8(11):865-73 [18923434.001]
  • [Cites] J Urol. 2009 Feb;181(2):849-60 [19095258.001]
  • [Cites] Am J Surg Pathol. 2009 Feb;33(2):241-7 [18941400.001]
  • [Cites] FASEB J. 2009 Mar;23(3):940-9 [19019854.001]
  • [Cites] Lancet. 2009 Mar 28;373(9669):1119-32 [19269025.001]
  • [Cites] BMC Med. 2009;7:9 [19291283.001]
  • [Cites] Am J Surg Pathol. 2009 May;33(5):739-48 [19238077.001]
  • [Cites] J Biol Chem. 2009 May 1;284(18):11942-52 [19246456.001]
  • [Cites] Int J Urol. 2009 May;16(5):432-43 [19453547.001]
  • [Cites] Int J Cancer. 2009 Jul 15;125(2):474-82 [19391132.001]
  • [Cites] Lancet Oncol. 2009 Aug;10(8):764-71 [19576851.001]
  • [Cites] J Pathol. 2002 Feb;196(2):186-93 [11793370.001]
  • (PMID = 20454689.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ANGPTL4 protein, human; 0 / Angiopoietins; 0 / Biomarkers; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC2861680
  •  go-up   go-down


24. Kato N, Sasou S, Motoyama T: Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol; 2006 Jan;19(1):83-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary.
  • Clear cell tumors of the ovary are frequently associated with ovarian endometriosis.
  • Clinicopathologically, it has been suggested that clear cell tumors develop from endometriosis, but there has been little molecular evidence supporting this speculation.
  • Microarray analysis revealed recently that hepatocyte nuclear factor-1beta (HNF-1beta) was significantly upregulated in clear cell carcinoma of the ovary.
  • In the present study, we examined 30 clear cell tumors (26 malignant, three borderline, and one benign) and 40 endometriotic cysts to clarify if differentiation into the clear cell lineage already begins in ovarian endometriosis.
  • All of the 30 clear cell tumors, including borderline and benign ones, showed immunohistochemical expression of HNF-1beta in the nucleus, while other types of ovarian epithelial tumors (endometrioid, serous, mucinous, and Brenner tumors) rarely expressed it.
  • Among 30 clear cell tumors, 17 (56%) cases were associated with endometriosis, and endometriotic epithelium was identified in 12 cases.
  • In nine of the 12 cases, distinct nuclear immunostaining for HNF-1beta was detected in the endometriotic epithelium, as well as in the clear cell tumor.
  • Our results indicate that HNF-1beta is an excellent molecular marker for ovarian clear cell tumors, including benign, borderline and malignant lesions.
  • Early differentiation into the clear cell lineage takes place in ovarian endometriosis, not only in atypical endometriosis, but also in endometriosis with degenerative and regenerative changes, and this is probably responsible for the frequent occurrence of clear cell carcinoma in ovarian endometriosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometriosis / pathology. Hepatocyte Nuclear Factor 1-beta / biosynthesis. Ovarian Diseases / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258507.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


25. Brustmann H: Poly(ADP-ribose) polymerase (PARP) and DNA-fragmentation factor (DFF45): expression and correlation in normal, hyperplastic and neoplastic endometrial tissues. Pathol Res Pract; 2007;203(2):65-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study evaluated the immunohistochemical expression of poly(ADP-ribose) polymerase (PARP) and DNA fragmentation factor 45 (DFF45) in normal endometria (NE, n=13), non-atypical (NAH, n=22) and atypical hyperplasia (AH, n=14), endometrioid carcinoma (EC, n=34), serous carcinoma (SC, n=10), and clear cell carcinoma (CCC, n=2).
  • PARP immunoreactivity increased significantly from NE via NAH to AH (P=0.0004), and decreased from AH to endometrial carcinomas (P=0.0054).
  • No significant differences were calculated between AH and endometrial carcinomas (P=0.7495).
  • Immunoexpression of PARP and DFF45 is apparently altered in endometrial carcinomas as compared with non-neoplastic endometrial tissues, indicating impaired mechanisms of apoptosis in the former.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis. Apoptosis Regulatory Proteins / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Poly(ADP-ribose) Polymerases / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cytoplasm / metabolism. Cytoplasm / pathology. DNA Fragmentation. Female. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17258405.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / caspase-activated DNase inhibitor; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  •  go-up   go-down


26. Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Yamada H, Yamamoto R, Sakuragi N, Enokida H, Verma M, Dahiya R: WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer; 2005 Nov 1;104(9):1924-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma.
  • BACKGROUND: Ovarian clear cell adenocarcinoma is associated with one of the poorest prognoses among human epithelial ovarian cancers.
  • The authors hypothesized that Wilms tumor suppressor 1 gene (WT1) sense and antisense (WT1-AS) expression and their promoter methylation status could characterize ovarian clear cell adenocarcinoma from ovarian serous adenocarcinoma.
  • METHODS: To test this hypothesis, ovarian cancer cell lines and 42 cancer tissues (17 clear cell and 25 serous adenocarcinoma) were analyzed for expression and methylation of WT1 and WT1-AS genes.
  • RESULTS: These experiments demonstrated that all serous adenocarcinoma tissues expressed both WT1 and WT1-AS genes, although expression of these genes was lacking in clear cell adenocarcinoma.
  • The WT1 and WT1-AS promoter were significantly methylated in clear cell adenocarcinoma (88.2% and 88.2%, respectively) compared with serous adenocarcinoma (24.0% and 20.0%, respectively).
  • Also in agreement with these data, WT1 and WT1-AS negative ovarian cancer cell lines reexpressed these genes after treatment with the demethylating agent, 5-aza-2'-deoxycytidine.
  • CONCLUSIONS: The current study shows that CpG hypermethylation is an important mechanism of WT1 and WT1-AS gene inactivation in ovarian clear cell adenocarcinoma.
  • This is the first report that has demonstrated differential expression and methylation of WT1-AS in ovarian clear cell and serous adenocarcinomas.
  • This study presents new molecular characterizations between these two types of adenocarcinoma and may provide insight as to why clear cell adenocarcinoma has a poorer prognosis than serous adenocarcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Cystadenocarcinoma, Serous / genetics. DNA Methylation. DNA, Antisense / metabolism. Ovarian Neoplasms / genetics. WT1 Proteins / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 16134181.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01AG21418; United States / NCI NIH HHS / CA / R01CA101844; United States / NIDDK NIH HHS / DK / T32DK07790
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Antisense; 0 / WT1 Proteins
  •  go-up   go-down


27. Byrne JA, Maleki S, Hardy JR, Gloss BS, Murali R, Scurry JP, Fanayan S, Emmanuel C, Hacker NF, Sutherland RL, Defazio A, O'Brien PM: MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer; 2010;10:497
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
  • BACKGROUND: The four-transmembrane MAL2 protein is frequently overexpressed in breast carcinoma, and MAL2 overexpression is associated with gain of the corresponding locus at chromosome 8q24.12.
  • Independent expression microarray studies predict MAL2 overexpression in ovarian carcinoma, but these had remained unconfirmed.
  • MAL2 binds tumor protein D52 (TPD52), which is frequently overexpressed in ovarian carcinoma, but the clinical significance of MAL2 and TPD52 overexpression was unknown.
  • METHODS: Immunohistochemical analyses of MAL2 and TPD52 expression were performed using tissue microarray sections including benign, borderline and malignant epithelial ovarian tumours.
  • RESULTS: MAL2 and TPD52 were significantly overexpressed in high-grade serous carcinomas compared with serous borderline tumours.
  • MAL2 expression was highest in serous carcinomas relative to other histological subtypes, whereas TPD52 expression was highest in clear cell carcinomas.
  • MAL2 expression was not related to patient survival, however high-level TPD52 staining was significantly associated with improved overall survival in patients with stage III serous ovarian carcinoma (log-rank test, p < 0.001; n = 124) and was an independent predictor of survival in the overall carcinoma cohort (hazard ratio (HR), 0.498; 95% confidence interval (CI), 0.34-0.728; p < 0.001; n = 221), and in serous carcinomas (HR, 0.440; 95% CI, 0.294-0.658; p < 0.001; n = 182).
  • CONCLUSIONS: MAL2 is frequently overexpressed in ovarian carcinoma, and TPD52 overexpression is a favourable independent prognostic marker of potential value in the management of ovarian carcinoma patients.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Endometrial Neoplasms / metabolism. Neoplasm Proteins / metabolism. Ovarian Neoplasms / metabolism. Proteolipids / metabolism. Vesicular Transport Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Chest. 2004 May;125(5):1843-52 [15136399.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4427-36 [15240533.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 24;325(4):1115-21 [15555543.001]
  • [Cites] Oncogene. 2005 Mar 3;24(10):1794-801 [15688027.001]
  • [Cites] Mol Cancer. 2005;4:26 [16042759.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):1049-54 [15986428.001]
  • [Cites] Nat Clin Pract Oncol. 2005 May;2(5):246-54 [16264960.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8577-84 [16361540.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1354-62 [16452189.001]
  • [Cites] Oral Oncol. 2006 Mar;42(3):306-16 [16321566.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):421-30 [16518402.001]
  • [Cites] BMC Cancer. 2006;6:92 [16608533.001]
  • [Cites] Oncogene. 2006 Nov 23;25(55):7324-32 [16751803.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):6937-45 [17145811.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):217-26 [17229949.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1511-7 [17192896.001]
  • [Cites] Mol Cancer Res. 2007 Feb;5(2):133-44 [17314271.001]
  • [Cites] PLoS One. 2007;2(3):e323 [17389914.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4731-9 [17699850.001]
  • [Cites] J Pathol. 2007 Sep;213(1):46-55 [17668415.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8906-13 [17875733.001]
  • [Cites] BMC Cancer. 2007;7:226 [18088415.001]
  • [Cites] BMC Syst Biol. 2008;2:2 [18173842.001]
  • [Cites] Br J Cancer. 2008 Jun 17;98(12):1999-2005 [18506145.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5050-60 [18698023.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5198-208 [18698038.001]
  • [Cites] Mol Cancer Res. 2008 Oct;6(10):1544-53 [18922970.001]
  • [Cites] Crit Rev Oncog. 2008;14(1):33-55 [19105569.001]
  • [Cites] BMC Cell Biol. 2009;10:7 [19175940.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2269-80 [19293255.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):3795-801 [19336569.001]
  • [Cites] Nat Rev Cancer. 2009 Jun;9(6):415-28 [19461667.001]
  • [Cites] J Proteome Res. 2009 Mar;8(3):1452-63 [19159301.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jul;116(2):281-94 [18642118.001]
  • [Cites] Fertil Steril. 2010 Sep;94(4):1212-7 [19643405.001]
  • [Cites] Oncology. 2000 Jun;59(1):50-6 [10895067.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):28866-72 [11384973.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5895-904 [11479231.001]
  • [Cites] Genomics. 2001 Aug;76(1-3):81-8 [11549320.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12963-8 [12297621.001]
  • [Cites] J Cell Biol. 2002 Oct 14;159(1):37-44 [12370246.001]
  • [Cites] Trends Biochem Sci. 2002 Dec;27(12):599-601 [12468223.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8861-8 [14695203.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Genome Res. 2004 Jun;14(6):1085-94 [15173114.001]
  • (PMID = 20846453.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MAL2 protein, human; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / Neoplasm Proteins; 0 / Proteolipids; 0 / TPD52 protein, human; 0 / Vesicular Transport Proteins
  • [Other-IDs] NLM/ PMC2949808
  •  go-up   go-down


28. Dionigi G, Uccella S, Gandolfo M, Lai A, Bertocchi V, Rovera F, Tanda ML: Solitary intrathyroidal metastasis of renal clear cell carcinoma in a toxic substernal multinodular goiter. Thyroid Res; 2008;1(1):6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary intrathyroidal metastasis of renal clear cell carcinoma in a toxic substernal multinodular goiter.
  • She had a history of renal clear cell carcinoma of the left kidney, which had been resected 2 years previously.
  • A histological examination revealed a solitary metastasis of a clear cell renal cancer in a diffuse multinodular goiter.
  • The diagnosis can be suspected if the patient has a thyroid tumor and a past history of extrathyroid cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr J. 2008 May;55(2):359-64 [18379125.001]
  • [Cites] Thyroid. 1999 Dec;9(12):1273-80 [10646671.001]
  • [Cites] Thyroid. 2008 Jan;18(1):85-7 [17887930.001]
  • [Cites] World J Surg. 2007 May;31(5):879-87 [17308849.001]
  • [Cites] Eur J Surg Oncol. 2007 Feb;33(1):83-5 [17085008.001]
  • [Cites] Langenbecks Arch Surg. 2006 Nov;391(6):581-7 [16983577.001]
  • [Cites] Eur J Endocrinol. 2006 Jun;154(6):787-803 [16728537.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):698-701 [16021578.001]
  • [Cites] Ann Surg. 1960 Apr;151:551-61 [13820008.001]
  • [Cites] Cancer. 1956 Mar-Apr;9(2):306-9 [13304848.001]
  • [Cites] Ann Surg. 1964 Aug;160:169-77 [14209716.001]
  • [Cites] Cancer. 1962 May-Jun;15:557-65 [13911946.001]
  • [Cites] AMA Arch Pathol. 1955 Mar;59(3):291-311 [14349472.001]
  • [Cites] World J Surg. 1999 Feb;23(2):177-80; discussion 181 [9880428.001]
  • [Cites] Thyroid. 1998 Feb;8(2):149-53 [9510123.001]
  • [Cites] Am J Clin Pathol. 1998 Mar;109(3):294-301 [9495201.001]
  • [Cites] Arch Pathol Lab Med. 1998 Jan;122(1):37-41 [9448014.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):574-8 [9028370.001]
  • [Cites] Ann Surg Oncol. 1995 May;2(3):252-6 [7641022.001]
  • [Cites] Endocrinol Metab Clin North Am. 1990 Sep;19(3):637-48 [2261909.001]
  • [Cites] Cancer. 1989 May 1;63(9):1810-5 [2649228.001]
  • [Cites] Tumori. 1987 Apr 30;73(2):187-90 [3554676.001]
  • [Cites] Mayo Clin Proc. 1984 Dec;59(12):856-9 [6503368.001]
  • [Cites] Pathol Res Pract. 1985 May;179(6):666-72 [4022843.001]
  • [Cites] Surg Gynecol Obstet. 1982 Oct;155(4):503-5 [7123465.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1487-91 [7272969.001]
  • [Cites] Acta Otolaryngol. 1969 May;67(5):552-62 [5378598.001]
  • [Cites] J Pathol. 1974 May;113(1):21-5 [4412457.001]
  • [Cites] Eur J Surg Oncol. 2004 Aug;30(6):583-8 [15256229.001]
  • [Cites] Thyroid. 2004 Jan;14(1):65-70 [15009916.001]
  • [Cites] Cancer. 2002 Nov 1;95(9):1869-78 [12404280.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Oct;57(4):551-6 [12354139.001]
  • [Cites] Surg Today. 2002;32(2):151-4 [11998944.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1149-58 [10699906.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2008 Apr;16(2):158-62 [18327036.001]
  • (PMID = 19014412.001).
  • [ISSN] 1756-6614
  • [Journal-full-title] Thyroid research
  • [ISO-abbreviation] Thyroid Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2596782
  •  go-up   go-down


29. Verhoest G, Manunta A, Bensalah K, Vincendeau S, Rioux-Leclercq N, Guillé F, Patard JJ: Laparoscopic partial nephrectomy with clamping of the renal parenchyma: initial experience. Eur Urol; 2007 Nov;52(5):1340-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Final pathologic examination revealed clear cell carcinoma in three cases and angiomyolipoma and oncocytoma in one case each.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Hemostasis, Endoscopic / methods. Kidney Neoplasms / surgery. Laparoscopy / methods. Nephrectomy / methods. Reperfusion Injury / prevention & control

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2007 Nov;52(5):1303-5 [17566640.001]
  • (PMID = 17498865.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


30. Lin YG, Deavers M, Sasan F, Zager JS, Ramondetta LM: Clinical challenges presented by three simultaneous solid tumors. Gynecol Oncol; 2006 Dec;103(3):1159-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The simultaneous presentation of cervical carcinoma, renal cell carcinoma, and appendiceal carcinoma has not been previously described.
  • During her workup, she was diagnosed with mucinous appendiceal carcinoma and clear cell carcinoma of the kidney.
  • One year following surgery, she remains without evidence of disease and with continually improving nutritional status.
  • [MeSH-major] Neoplasms, Multiple Primary / diagnosis
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / therapy. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / therapy. Appendiceal Neoplasms / diagnosis. Appendiceal Neoplasms / pathology. Appendiceal Neoplasms / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / pathology. Kidney Neoplasms / therapy. Middle Aged. Neoplasm Staging. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17055558.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


31. Kim DJ, Lee MH, Park TI, Bae HI: Expression and mutational analysis of c-kit in ovarian surface epithelial tumors. J Korean Med Sci; 2006 Feb;21(1):81-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cases consisted of 33 cases, which included 13 serous cystadenocarcinomas, 1 borderline serous tumor, 8 mucinous cystadenocarcinomas, 6 borderline mucinous tumors and 5 clear cell carcinomas.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Urol. 1996;14(5):347-52 [8912475.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):281-304 [9633841.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1643-7 [10362788.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):2048-55 [15583695.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1213-20 [10534170.001]
  • [Cites] Biol Reprod. 2000 Jun;62(6):1600-9 [10819761.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):242-50 [10861500.001]
  • [Cites] Leuk Res. 2001 Jul;25(7):571-6 [11377682.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]
  • [Cites] Hum Pathol. 2002 May;33(5):484-95 [12094373.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):758-64 [12910520.001]
  • [Cites] Oncologist. 2003;8(6):531-8 [14657531.001]
  • [Cites] Ann Oncol. 2004 Apr;15(4):594-7 [15033665.001]
  • [Cites] EMBO J. 1987 Nov;6(11):3341-51 [2448137.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2416-9 [1707753.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3049-53 [7514496.001]
  • [Cites] Br J Cancer. 1996 May;73(10):1233-6 [8630284.001]
  • [Cites] Hum Pathol. 2005 Mar;36(3):242-9 [15791568.001]
  • (PMID = 16479070.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC2733984
  •  go-up   go-down


32. Suhail M: Na, K-ATPase: Ubiquitous Multifunctional Transmembrane Protein and its Relevance to Various Pathophysiological Conditions. J Clin Med Res; 2010 Feb;2(1):1-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Na(+), K(+)-ATPase (NKA) is an ubiquitous enzyme consisting of α, β and γ subunits, and is responsible for the creation and maintenance of the Na(+) and K(+) gradients across the cell membrane by transporting 3 Na(+) out and 2 K(+) into the cell.
  • Identification of naturally occurring regulators of  NKA could initiate the discovery of new hormone-like control systems involved in the etiology of selected disease processes, hence the importance of understanding the relation of the sodium pump and its ligands to disease.
  • NKA is also involved in hypertension, salt balance, cardiovascular and renal disorders, sperm capacitation, cell volume regulation, apoptosis, rheumatoid arthritis, sepsis, neurological disorders, lung edema clearance and preeclampsia.
  • NKA enzyme activity and subunit levels are reduced in carcinoma, NKA-β levels were highly reduced in an invasive form of human renal clear cell carcinoma, androgen-dependent prostate cancer, in early stages of urothelial cancer, as well as in poorly differentiated, highly motile carcinoma cell lines obtained from various tissues suggesting a functional link between reduced NKA-β expression and cancer progression.
  • It could be a target for the development of anticancer drugs as it serves as a signal transducer, it is a player in cell adhesion and its aberrant expression and activity are implicated in the development and progression of different cancers.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22457695.001).
  • [ISSN] 1918-3003
  • [Journal-full-title] Journal of clinical medicine research
  • [ISO-abbreviation] J Clin Med Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3299169
  •  go-up   go-down


33. Sioutopoulou DO, Kampas LI, Gerasimidou D, Valeri RM, Boukovinas I, Tsavdaridis D, Destouni CT: Diagnosis of metastatic tumors in cerebrospinal fluid samples using thin-layer cytology. Acta Cytol; 2008 May-Jun;52(3):304-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of metastatic tumors in cerebrospinal fluid samples using thin-layer cytology.
  • OBJECTIVE: To evaluate the application of ThinPrep liquid-based cytology (LBC) and present our experience using LBC in the diagnosis of metastatic tumors in cerebrospinal fluid (CSF) samples.
  • RESULTS: ThinPrep technology provided preservation of cytomorphologic features, high cellularity per slide and clear background.
  • Analysis revealed 8 breast carcinomas, 5 lung carcinomas, 4 lymphomas, 3 adenocarcinomas of the gastrointestinal tract, 1 squamous cell carcinoma of uterine cervix and 1 urinary bladder carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cerebrospinal Fluid / cytology. Cytodiagnosis. Cytological Techniques / methods. Neoplasm Metastasis / diagnosis

  • Hazardous Substances Data Bank. BIOTIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540294.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 1405-69-2 / Avidin; 6SO6U10H04 / Biotin
  •  go-up   go-down


34. Garzon JC, Lai FM, Mok TS, Manlulu AV, Ng CS, Lee TW, Yim AP: Clear cell carcinoma of the lung revisited. J Thorac Cardiovasc Surg; 2005 Oct;130(4):1198-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the lung revisited.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16214540.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Troisi R, Hatch EE, Titus-Ernstoff L, Hyer M, Palmer JR, Robboy SJ, Strohsnitter WC, Kaufman R, Herbst AL, Hoover RN: Cancer risk in women prenatally exposed to diethylstilbestrol. Int J Cancer; 2007 Jul 15;121(2):356-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prenatal diethylstilbestrol (DES) exposure is associated with excess risks of clear cell adenocarcinoma (CCA), and breast cancer in older women.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17390375.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens, Non-Steroidal; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


36. Godfrey GJ, Moore G, Alatassi H: Presentation of renal cell carcinoma as cervical polyp metastasis. J Low Genit Tract Dis; 2010 Oct;14(4):387-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presentation of renal cell carcinoma as cervical polyp metastasis.
  • Secondary cervical adenocarcinomas are most commonly seen owing to the extension of a primary endometrial adenocarcinoma.
  • We report a case of metastatic renal cell carcinoma, clear cell variant, to the cervix, which presented as a cervical polyp in a postmenopausal female.
  • To our knowledge, this is the fourth reported case of renal cell carcinoma metastatic to the cervix.
  • This case is only the third in which the cervical metastasis was the presenting sign of renal cell carcinoma and the first in which the clinical presentation was as a cervical polyp.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / secondary. Polyps / pathology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / secondary
  • [MeSH-minor] Female. Histocytochemistry. Humans. Microscopy. Middle Aged. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / pathology


37. Michal M, Hes O, Nemcova J, Sima R, Kuroda N, Bulimbasic S, Franco M, Sakaida N, Danis D, Kazakov DV, Ohe C, Hora M: Renal angiomyoadenomatous tumor: morphologic, immunohistochemical, and molecular genetic study of a distinct entity. Virchows Arch; 2009 Jan;454(1):89-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal angiomyoadenomatous tumor: morphologic, immunohistochemical, and molecular genetic study of a distinct entity.
  • The tumors were composed of admixture of an epithelial clear cell component and prominent leiomyomatous stroma.
  • All tubular/glandular structures were lined by a fine capillary network.
  • RAT is a distinct morphologic entity, being different morphologically, immunohistochemically, and genetically from all renal tumors including conventional clear cell carcinoma and mixed epithelial and stromal tumor of kidney.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Virchows Arch. 2009 Apr;454(4):479-80 [19205727.001]
  • [Cites] Radiology. 1983 Feb;146(2):309-21 [6294736.001]
  • [Cites] Am J Surg Pathol. 2006 Nov;30(11):1372-81 [17063076.001]
  • [Cites] Eur Urol. 1987;13(4):276-80 [2820738.001]
  • [Cites] Pathol Res Pract. 1993 Sep;189(8):951-6; discussion 957-9 [8302716.001]
  • [Cites] Am J Surg Pathol. 2008 Mar;32(3):377-82 [18300814.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):220-1 [12861412.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):359-67 [15322873.001]
  • [Cites] Pathol Res Pract. 2000;196(4):275-6 [10782473.001]
  • [Cites] Pathol Int. 2005 Mar;55(3):150-4 [15743324.001]
  • [Cites] Ann Diagn Pathol. 1998 Feb;2(1):12-8 [9845718.001]
  • [Cites] Ultrastruct Pathol. 1988 Jan-Feb;12(1):131-6 [3354071.001]
  • [Cites] Ann Diagn Pathol. 2000 Oct;4(5):311-5 [11073338.001]
  • [Cites] Virchows Arch. 2005 Sep;447(3):669-71 [16025280.001]
  • [Cites] J Clin Pathol. 2007 Jan;60(1):98-100 [17213356.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):203-10 [10680888.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):700-2 [11764393.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):962-6 [15223969.001]
  • [Cites] Br J Urol. 1977 Nov;49(6):441-6 [588942.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1239-45 [18594469.001]
  • [Cites] Pathol Res Pract. 1998;194(6):445-8 [9689654.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):958-70 [10895818.001]
  • (PMID = 19020896.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CAM 5.2 antigen; 0 / Keratin-20; 0 / Keratin-7; 0 / Mucin-1; 0 / Vimentin; 68238-35-7 / Keratins; EC 2.3.2.27 / Von Hippel-Lindau Tumor Suppressor Protein; EC 6.3.2.- / VHL protein, human
  •  go-up   go-down


38. Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H: Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol; 2010 Dec 27;2(12):419-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To date, ICC was largely classified into adenocarcinoma and rare variants.
  • That is, ICC is classifiable into the conventional (bile duct) type, the bile ductular type, the intraductal neoplasm type and rare variants.
  • The conventional type is further divided into the small duct type (peripheral type) and large bile duct type (perihilar type).
  • The former is a tubular or micropapillary adenocarcinoma while the latter involves the intrahepatic large bile duct.
  • Bile ductular type resembles proliferated bile ductules and shows a replacing growth of the hepatic parenchyma.
  • Hepatic progenitor cell or stem cell phenotypes such as neural cell adhesion molecule expression are frequently expressed in the bile ductular type.
  • Intraductal type includes papillary and tubular neoplasms of the bile duct (IPNBs and ITNBs) and a superficial spreading type.
  • IPNB and ITNB show a spectrum from a preneoplastic borderline lesion to carcinoma and may have pancreatic counterparts.
  • At invasive sites, IPNB is associated with the conventional bile duct ICC and mucinous carcinoma.
  • Rare variants of ICC include squamous/adenosquamous cell carcinoma, mucinous/signet ring cell carcinoma, clear cell type, undifferentiated type, neuroendocrine carcinoma and so on.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2008 Jun;215(2):175-83 [18393368.001]
  • [Cites] Mod Pathol. 2001 May;14(5):527-32 [11353065.001]
  • [Cites] J Clin Gastroenterol. 1994 Jun;18(4):335-42 [8071522.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1739-45 [15185318.001]
  • [Cites] Hepatology. 2006 Nov;44(5):1333-43 [17058219.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):350-8 [16360234.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(4):288-91 [14598147.001]
  • [Cites] Hepatol Res. 2007 Oct;37 Suppl 3:S478-86 [17931207.001]
  • [Cites] Histopathology. 1980 Jul;4(4):391-400 [6253379.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):651-8 [11584359.001]
  • [Cites] World J Hepatol. 2009 Oct 31;1(1):35-42 [21160963.001]
  • [Cites] Lab Invest. 2009 Nov;89(11):1261-74 [19721413.001]
  • [Cites] Hepatol Res. 2008 Apr;38(4):325-34 [18093122.001]
  • [Cites] J Hepatol. 2006 Dec;45(6):856-67 [17030071.001]
  • [Cites] Microsc Res Tech. 1997 Sep 15;38(6):552-70 [9330346.001]
  • [Cites] Am J Pathol. 2009 Mar;174(3):829-41 [19218340.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1243-54 [16741522.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2145-9 [9610693.001]
  • [Cites] Cancer. 1977 Jan;39(1):232-46 [64293.001]
  • [Cites] Pathol Int. 2010 Jun;60(6):419-29 [20518896.001]
  • [Cites] Pathol Int. 2010 Jul;60(7):516-9 [20594273.001]
  • [Cites] Mod Pathol. 2007 Jun;20(6):701-9 [17431410.001]
  • [Cites] Curr Gastroenterol Rep. 2006 Feb;8(1):30-7 [16510032.001]
  • [Cites] Pathol Int. 2005 Apr;55(4):180-8 [15826244.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1193-203 [15316319.001]
  • [Cites] Hum Pathol. 2003 Dec;34(12):1337-44 [14691921.001]
  • [Cites] Histopathology. 2007 Sep;51(3):390-400 [17553067.001]
  • (PMID = 21191517.001).
  • [ISSN] 1948-5182
  • [Journal-full-title] World journal of hepatology
  • [ISO-abbreviation] World J Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3010511
  • [Keywords] NOTNLM ; Adenocarcinoma / Bile duct / Bile ductule / Intraductal neoplasm / Intrahepatic cholangiocarcinoma
  •  go-up   go-down


39. Lax SF: Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Pathology; 2007 Feb;39(1):46-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrial carcinoma, endometrial stromal tumours and mixed malignant mesodermal tumours (MMMT) develop along distinctive molecular genetic pathways.
  • Two distinctive types of endometrial carcinoma are distinguished, type I and type II, which develop along distinctive pathways and show different clinical behaviour and histological features.
  • Type I carcinomas show endometrioid histology, are oestrogen-related and develop from atypical endometrial hyperplasia.
  • The molecular tumorigenesis is comparable to colorectal carcinoma with a step-like progression and an accumulation of genetic alterations.
  • Alterations of PTEN, K-Ras mutations and microsatellite instability are frequent and early events in type I carcinoma, whereas p53 mutations occur during progression to grade 3 carcinoma.
  • Serous and clear cell carcinomas are considered type II carcinomas which are mostly unrelated to oestrogen. p53 mutations occur in almost all serous carcinomas and seem to occur early, leading to massive chromosomal instability and rapid tumour progression.
  • Gene expression profiling has supported this dualistic model of endometrial carcinoma.
  • There is evidence of molecular differences between serous and clear cell carcinomas as well as between endometrioid carcinomas with and without microsatellite instability.
  • Endometrial stromal sarcomas (ESS; type I endometrial sarcoma) are oestrogen-related and seem to develop from endometrial stromal nodules (ESN).
  • They are histologically and genetically distinct from undifferentiated endometrial sarcoma (UES) which seem to be mostly unrelated to oestrogen (type II endometrial sarcoma).
  • In MMMT, which is considered a metaplastic carcinoma, p53 alteration occurs early, before clonal expansion and acquisition of genetic diversity during progression.
  • [MeSH-major] Endometrial Neoplasms / genetics. Endometrial Stromal Tumors / genetics. Molecular Biology. Neoplasms, Glandular and Epithelial / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17365822.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 82
  •  go-up   go-down


40. Soda T, Nishimura K, Kobayashi Y, Kato T, Tokugawa S, Kishikawa H, Ihara H, Ichikawa Y: [A case of synchronous contralateral renal cell carcinoma and urothelial carcinoma]. Hinyokika Kiyo; 2009 Aug;55(8):491-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of synchronous contralateral renal cell carcinoma and urothelial carcinoma].
  • Histological examination findings showed that the right renal tumor was a renal cell carcinoma, clear cell type, G1, INFalpha, pT2, ly0, v0, and that the splenic tumor was an arteriovenous fistula.
  • Next, transurethral resection of the bladder tumor was performed and a histological examination showed urothelial carcinoma.
  • Left total nephroureterectomy and cystectomy were performed, and the histological diagnosis was urothelial carcinoma, G3, pT3, ly1, v2.
  • It is rare for a renal cell carcinoma and contralateral renal pelvic cancer to occur simultaneously, as only 15 cases including the present have been reported in Japan.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Kidney Pelvis. Neoplasms, Multiple Primary / pathology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764535.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


41. Staats PN, Clement PB, Young RH: Primary endometrioid adenocarcinoma of the vagina: a clinicopathologic study of 18 cases. Am J Surg Pathol; 2007 Oct;31(10):1490-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary endometrioid adenocarcinoma of the vagina: a clinicopathologic study of 18 cases.
  • Vaginal adenocarcinoma is the second most common primary cancer of the vagina, yet there has been very little study of most subtypes other than clear cell carcinoma.
  • We reviewed 18 cases of primary vaginal endometrioid adenocarcinoma, in our experience the second most common subtype.
  • On microscopic examination, each of the tumors had a pure or predominant component of typical endometrioid adenocarcinoma.
  • Other subtypes of adenocarcinoma (such as serous when the tumor has a papillary pattern) and atypical forms of endometriosis, including polypoid endometriosis, are the most common other differential diagnostic considerations.
  • The prognosis seems to be good in low-stage patients, with 11 patients alive and well and 2 alive with recurrent disease.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Cystadenocarcinoma, Serous / diagnosis. Diagnosis, Differential. Endometriosis / complications. Endometriosis / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895749.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Duda-Szymańska J, Kaczmarek J, Papierz W: Cystic nephroma in adults. A report of two cases and review of the literature. Pol J Pathol; 2005;56(2):93-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In both patients the results of ultrasound and clinical examinations were not characteristic enough to establish the precise preoperative diagnosis.
  • Due to the age of the patients and the location of the lesions, possibility of clear cell carcinoma with cystic changes was considered.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Renal Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. Ultrasonography

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16092672.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


43. Gasljevic G, Lamovec J: Primary clear cell adenocarcinoma of the rectum: a case report. Int J Colorectal Dis; 2010 Oct;25(10):1259-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell adenocarcinoma of the rectum: a case report.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Disease-Free Survival. Endoscopy, Gastrointestinal. Humans. Laparoscopy. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20405292.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


44. Hiromura T, Tanaka YO, Nishioka T, Satoh M, Tomita K: Clear cell adenocarcinoma of the uterine cervix arising from a background of cervical endometriosis. Br J Radiol; 2009 Jan;82(973):e20-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the uterine cervix arising from a background of cervical endometriosis.
  • The radiological findings of cervical clear cell adenocarcinoma (CCA) have not been described previously.
  • [MeSH-major] Adenocarcinoma, Clear Cell / etiology. Endometriosis / complications. Uterine Cervical Neoplasms / etiology


45. Orezzoli JP, Russell AH, Oliva E, Del Carmen MG, Eichhorn J, Fuller AF: Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol; 2008 Sep;110(3):336-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implication of endometriosis in clear cell carcinoma of the ovary.
  • OBJECTIVE: The aim of this study is to investigate whether the presence of endometriosis is a prognostic factor in patients diagnosed with clear cell carcinoma (CCC) of the ovary.
  • Advanced tumor stage at diagnosis (HR 13, 95% C.I.
  • Disease recurrence or death among optimally and completely cytoreduced patients was 31% and 59% for those with and without endometriosis respectively (P>0.05).
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometriosis / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18639330.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds
  •  go-up   go-down


46. Gütgemann I, Lehman NL, Jackson PK, Longacre TA: Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Mod Pathol; 2008 Apr;21(4):445-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma.
  • Clear cell carcinoma is a clinically and pathologically distinct entity among surface epithelial ovarian neoplasms, recognized for its resistance to standard platinum-based chemotherapy at advanced stage disease and poor prognosis.
  • Despite advances in our understanding of the biology of other surface epithelial ovarian neoplasms, very little is known about the molecular genetic mechanisms that are involved in clear cell tumorigenesis.
  • Early mitotic inhibitor-1 (Emi1) protein is a key cell cycle regulator, that promotes S-phase and mitotic entry by inhibiting the anaphase promoting complex.
  • In cell culture systems, overexpression of Emi1 leads to tetraploidy and genomic instability, especially in the absence of normal p53 function.
  • We investigated Emi1 protein expression in ovarian neoplasms using a tissue microarray constructed from 339 primary ovarian surface epithelial (serous, endometrioid, clear cell, and mucinous) and peritoneal (serous) neoplasms, stromal and mesenchymal tumors, germ cell tumors, and normal ovarian tissue.
  • Significant overexpression of Emi1 protein was present in 82% (27/33) clear cell carcinoma, including one borderline tumor in a diffuse, granular cytoplasmic and perinuclear staining pattern, independent of patient age, presence of ovarian and/or pelvic endometriosis, and FIGO stage.
  • In contrast, only 10% (17/177) primary ovarian and primary peritoneal serous carcinomas, 0% (0/10) mucinous carcinomas, and 19% (6/32) endometrioid carcinomas exhibited significant Emi1 protein overexpression.
  • Accumulation of Emi1 protein was not linked to Ki-67 labeling index, but was directly correlated with cyclin E and inversely correlated with ER in clear cell carcinoma (P<0.001).
  • Emi1 protein expression was present in mixed endometrioid/clear cell tumors but absent in tumors with mixed serous/clear cell histology.
  • These findings represent a potentially important insight into the molecular pathway underlying ovarian carcinogenesis and provide a possible cell cycle model for the development and progression of ovarian clear cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Cell Cycle Proteins / biosynthesis. F-Box Proteins / biosynthesis. Ovarian Neoplasms / metabolism. Signal Transduction / physiology. Ubiquitin-Protein Ligase Complexes / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18204430.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin E; 0 / F-Box Proteins; 0 / FBXO5 protein, human; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; EC 6.3.2.19 / Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Ubiquitin-Protein Ligase Complexes
  •  go-up   go-down


47. Bats AS, Metzger U, Le Frere-Belda MA, Brisa M, Lecuru F: Malignant transformation of Gartner cyst. Int J Gynecol Cancer; 2009 Dec;19(9):1655-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of Gartner cyst.
  • Malignant transformation of Gartner cysts is exceedingly rare.
  • Histologic examination showed a clear cell carcinoma.
  • [MeSH-major] Cell Transformation, Neoplastic. Cysts / pathology. Vaginal Diseases / pathology. Wolffian Ducts / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Disease Progression. Female. Humans. Urogenital Neoplasms / diagnosis. Urogenital Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Vaginal Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955954.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Liu M, Wang JY, Zhang YG, Zhu SC, Lu ZH, Wan B: [Detection of urological and male genital tumors diagnosed in Beijing Hospital 1995 - 2004]. Zhonghua Yi Xue Za Zhi; 2007 Sep 11;87(34):2423-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The commonest malignancies included transitional cell carcinoma of bladder (n = 387), carcinoma of prostate (n = 271), and clear cell carcinoma of kidney (n = 250).
  • The ratio of metastatic carcinoma in prostate and kidney decreased with each passing year.
  • Before 1999 75.48% of the patients with prostate carcinoma visited the hospital because of low urinary tract symptom (LUTS), and only 12.48% because of abnormalities discovered during physical examination, However, after 2000 the percentage of the prostate carcinoma patients who visited the hospital because of LUST deceased to 54.44%, and those because of abnormalities discovered during physical examination increased to 40.99% (P < 0.01).
  • CONCLUSION: The improvement of diagnostic methods has changed the condition of tumor diagnosis in recent years.
  • [MeSH-major] Hospitalization / statistics & numerical data. Urogenital Neoplasms / diagnosis. Urogenital Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. China / epidemiology. Cross-Sectional Studies. Female. Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / epidemiology. Male. Middle Aged. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / epidemiology. Retrospective Studies. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036323.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


49. Ejaz AA, Geiger XJ, Wasiluk A: Focal segmental glomerulosclerosis in kidney resected for renal cell carcinoma. Int Urol Nephrol; 2005;37(2):345-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal segmental glomerulosclerosis in kidney resected for renal cell carcinoma.
  • A diagnosis of renal dysfunction is usually made on the basis of clinical, biochemical, radiologic, and renal tissue analysis.
  • Accurate diagnosis often requires a renal biopsy, but that procedure is contraindicated in certain clinical circumstances, particularly in patients who have only one kidney.
  • We describe a patient who previously had undergone left nephrectomy for a renal clear cell carcinoma, in whom the diagnosis of focal segmental glomerulosclerosis was made on retrospective analysis of remnant renal tissue from the patient's nephrectomy specimen.
  • [MeSH-major] Carcinoma, Renal Cell / complications. Glomerulosclerosis, Focal Segmental / complications. Kidney Neoplasms / complications


50. Will TA, Agarwal N, Petruzzelli GJ: Oral cavity metastasis of renal cell carcinoma: a case report. J Med Case Rep; 2008;2:313
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral cavity metastasis of renal cell carcinoma: a case report.
  • INTRODUCTION: Despite being reported rarely, renal cell carcinoma is the third most frequent neoplasm to metastasize to the head and neck region preceded only by breast and lung cancer.
  • Little information exists regarding the presentation and work-up of metastatic renal cell carcinoma in the oral cavity.
  • Immunoperoxidase testing was necessary to make the diagnosis of metastatic renal cell carcinoma and rule out other clear cell carcinomas of salivary gland origin.
  • CONCLUSION: Metastatic renal cell carcinoma is part of the differential diagnosis for patients presenting with a new head or neck lesion in the setting of a history of kidney cancer.
  • The physician needs to be prepared for the increased risk of bleeding and understand the importance of immunohistochemical staining to differentiate between metastatic renal cell carcinoma and malignancies of salivary origin.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Case Rep. 2008;2:249 [18657269.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):e76-8 [16504856.001]
  • [Cites] Hinyokika Kiyo. 2004 Nov;50(11):791-3 [15628540.001]
  • [Cites] Cardiovasc Intervent Radiol. 1991 Jan-Feb;14(1):50-4 [2044129.001]
  • [Cites] Mich Med. 1971 Jul;70(16):616-8 [5571989.001]
  • [Cites] Urol Oncol. 2004 May-Jun;22(3):214-23; discussion 223-4 [15271320.001]
  • [Cites] Acta Otolaryngol. 2004 Mar;124(2):197-201 [15072424.001]
  • [Cites] Laryngoscope. 2002 Sep;112(9):1598-602 [12352670.001]
  • [Cites] J Oral Maxillofac Surg. 2002 Aug;60(8):942-4 [12149744.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23):1655-9 [11759643.001]
  • (PMID = 18823541.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2566576
  •  go-up   go-down


51. Hynninen P, Vaskivuo L, Saarnio J, Haapasalo H, Kivelä J, Pastoreková S, Pastorek J, Waheed A, Sly WS, Puistola U, Parkkila S: Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology; 2006 Dec;49(6):594-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In malignant tumours, the staining was most prominent in hypoxic regions.
  • Expression of CA XII was detected in all tumour categories, although the mean staining intensity was weaker than for CA IX in all groups except for clear cell carcinomas.
  • The expression pattern of CA IX suggests that it could also serve as a useful histopathological marker protein for hypoxia in malignant ovarian tumours.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Carbonic Anhydrases / metabolism. Cell Membrane / enzymology. Cystadenocarcinoma, Mucinous / enzymology. Cystadenocarcinoma, Serous / enzymology. Cystadenoma, Mucinous / enzymology. Ovarian Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163844.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK40163
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Isoenzymes; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases; EC 4.2.1.1 / carbonic anhydrase XII
  •  go-up   go-down


52. Dimova I, Raitcheva S, Dimitrov R, Doganov N, Toncheva D: Correlations between c-myc gene copy-number and clinicopathological parameters of ovarian tumours. Eur J Cancer; 2006 Mar;42(5):674-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We established c-myc amplification in more than 30% in endometrioid and mixed epithelial ovarian carcinomas. c-myc gains were found in a high proportion (42.9%) of clear cell carcinomas.
  • We found associations between c-myc copy-number changes and clinicopathological parameters of ovarian tumours such as degree of malignancy and histological type.
  • We suggested that c-myc amplifications are characteristics for endometrioid, and c-myc gains for clear cell ovarian cancers.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458500.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; EC 2.7.11.1 / AURKA protein, human; EC 2.7.11.1 / Aurora Kinase A; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


53. Zhao J, Yart A, Frigerio S, Perren A, Schraml P, Weisstanner C, Stallmach T, Krek W, Moch H: Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene. Oncogene; 2007 May 17;26(23):3440-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the relevance of HRPT2 for sporadic renal tumors, clear cell, papillary and chromophobe renal cell carcinomas as well as oncocytomas and Wilms tumors were analysed for HRPT2 gene alterations.
  • Loss of heterozygosity (LOH) of HRPT2 was found in seven of 56 (12.5%) clear cell, three of 14 (21%) papillary, six of 10 (60%) chromophobe renal cell carcinomas, three of eight (38%) oncocytomas and four of 10 (40%) Wilms tumors.
  • In addition, two novel HRPT2 point mutations, causing K34Q and R292K changes in parafibromin, were detected in one clear cell carcinoma and one Wilms tumor, respectively.
  • These tumors displayed LOH of the remaining wild-type allele, but interestingly no von Hippel-Lindau (VHL) mutation.
  • Functional analysis revealed that the K34Q mutant species of parafibromin is, unlike wild-type protein, defective in suppressing cyclin D1 expression in vivo.
  • Taken together, these results suggest that renal cancer-associated mutations in parafibromin occur in the absence of VHL mutation, which in turn may contribute to constitutively elevated cyclin D1 expression and abnormal cell proliferation.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. L-Lysine .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17130827.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDC73 protein, human; 0 / Tumor Suppressor Proteins; K3Z4F929H6 / Lysine
  •  go-up   go-down


54. Takami M, Kita E, Kuwana Y, Ohta Y, Nakayama Y, Fukai H, Matsumoto H, Takimoto T, Ichikawa G, Yamamoto T: [A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1243-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin].
  • Clear-cell carcinoma of the ovary is a highly malignant neoplasm.
  • Survival of patients in the advanced stage is poor, and the best treatment is not clear.
  • We report here a case of a 57-year-old woman who had Stage IIIb advanced clearcell carcinoma of the ovary.
  • Considering the poor prognosis of clear-cell carcinoma, this regimen is thought to be effective for advanced clear-cell carcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Cisplatin / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633273.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


55. Kildal W, Risberg B, Abeler VM, Kristensen GB, Sudbø J, Nesland JM, Danielsen HE: beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients. Eur J Cancer; 2005 May;41(8):1127-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, the impact of beta-catenin expression on genomic instability in ovarian carcinoma, as determined by DNA ploidy, was investigated.
  • Expression of beta-catenin was examined by immunohistochemistry in 253 ovarian carcinomas.
  • Nuclear beta-catenin was almost exclusively present in endometroid carcinomas.
  • Mucinous carcinomas had the highest degree of cytoplasmic beta-catenin expression (92%), followed by endometroid (92%), mixed (90%), serous (82%), unclassified adenocarcinomas (81%), carcinomas clear cell and (70%), (P=0.01).
  • Tumours with differentiation grade 1 (16%) and 2 (24%) had higher nuclear beta-catenin expression than grade 3 and clear cell carcinomas (6%) (P=0.012).
  • In conclusion, the study showed no correlation between beta-catenin expression in ovarian carcinoma and FIGO stage and genomic instability as determined by DNA ploidy status.
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Immunohistochemistry. Observer Variation. beta Catenin

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15911235.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / DNA, Neoplasm; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


56. Mustea A, Pirvulescu C, Könsgen D, Braicu EI, Yuan S, Sun P, Lichtenegger W, Sehouli J: Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine; 2008 Apr;42(1):77-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The distribution of histological type of ovarian cancer was as follows: serous-papillary 43 (81.1%), 4 (7.5%) mucinous, 3 (5.7%) endometroid and 3 (5.7%) clear cell carcinoma.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18329282.001).
  • [ISSN] 1096-0023
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL1RN protein, human; 0 / Interleukin 1 Receptor Antagonist Protein; 0 / Interleukin-1alpha; 0 / Interleukin-1beta
  •  go-up   go-down


57. Castiblanco G A, Pires N Y, Wistuba O I, Riquelme S E, Andrade M L, Corvalán R A: [Pathogenic role of PTEN tumor suppressor gene in ovarian cancer associated to endometriosis]. Rev Med Chil; 2006 Mar;134(3):271-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Rol patogénico del gen supresor de tumores PTEN en cáncer ovárico asociado a endometriosis.
  • BACKGROUND: Endometrioid carcinoma and clear cell carcinoma of the ovary are associated to endometriosis.
  • Somatic mutations of PTEN (10q23.3) are present in endometrial endometrioid carcinoma.
  • AIM: To determine the cellular proliferation index using Ki 67, the immunohistochemical expression of PTEN and LOH in patients with ovarian endometriosis without atypia (EN), ovarian endometriosis with atypia (EA) and endometriosis with adjacent ovarian carcinoma (ET).
  • MATERIAL AND METHODS: Paraffin embedded samples of 37 endometrioid and clear cell carcinomas of the ovary (CC/CE), 15 solitary ovarian EN and 15 ovarian EA, were studied.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Carcinoma, Endometrioid / genetics. Endometriosis / genetics. Ovarian Neoplasms / genetics. PTEN Phosphohydrolase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Disease Progression. Female. Genetic Markers. Humans. Immunohistochemistry. Ki-67 Antigen / genetics. Ki-67 Antigen / metabolism. Loss of Heterozygosity / genetics. Middle Aged


58. Alvarez-Múgica M, Bulnes Vázquez V, Jalón Monzón A, Gil A, Rodríguez Robles L, Miranda Aranzubía O: Late recurrence from a renal cell carcinoma: solitary right maxilar mass 17 years after surgery. Arch Esp Urol; 2010 Mar;63(2):147-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrence from a renal cell carcinoma: solitary right maxilar mass 17 years after surgery.
  • OBJECTIVES: To report a new case of late renal cell carcinoma recurrence.
  • METHODS: Renal cell carcinoma represents approximately 3% of all adult malignancies.
  • The histological diagnosis of the referred mass was clear cell carcinoma.
  • Examination under general anaesthesia and biopsy was performed revealing metastasis of a renal cell carcinoma.
  • CONCLUSIONS: The natural history of renal cell carcinoma is highly variable, metastases may present decades after the removal of the primary disease, however, only 1% of patients with renal cell carcinoma have metastases confined only to the head and neck, and solitary cervical metastatic mass is rare.
  • Moreover, renal cell carcinoma should be considered in the differential diagnosis of any growing lesion in the head and neck.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Maxillary Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20378937.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


59. Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD: Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther; 2006 Jan;5(1):22-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor biopsies were taken before and after starting the drug to assess for microvessel density by CD 31 and cell proliferation by Ki67 immunohistochemistry.
  • A patient with clear cell carcinoma of the ovary had a partial response at 1600 mg bid dose level lasting over three years.
  • 2ME2 treatment had no effect on microvessel density (CD31 immunostaining) and cell proliferation (Ki-67 immunostaining).
  • [MeSH-minor] Administration, Oral. Adult. Apoptosis. Capillaries / drug effects. Cell Proliferation / drug effects. Female. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357512.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 4TI98Z838E / Estradiol; 6I2QW73SR5 / 2-methoxyestradiol
  •  go-up   go-down


60. Fijuth J: Brachytherapy in paediatric malignancies - review of indications. J Contemp Brachytherapy; 2010 Jun;2(2):81-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment strategies directed towards the reduction of late side effects have significantly increased interest in brachytherapy, in particular of soft tissue sarcoma and clear cell adenocarcinoma, as in these malignancies often only a limited target volume needs to be treated by a significant radiation dose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27829850.001).
  • [ISSN] 1689-832X
  • [Journal-full-title] Journal of contemporary brachytherapy
  • [ISO-abbreviation] J Contemp Brachytherapy
  • [Language] eng
  • [Publication-type] Review; Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; HDR / LDR / brachytherapy / paediatric malignancies
  •  go-up   go-down


61. Maran RR, Thomas A, Roth M, Sheng Z, Esterly N, Pinson D, Gao X, Zhang Y, Ganapathy V, Gonzalez FJ, Guo GL: Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther; 2009 Feb;328(2):469-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development.
  • The exact mechanism by which fat induces colon cancer is not clear, however, increased bile acid excretion in response to high-fat diet may promote colon carcinogenesis.
  • The current study evaluated the effects of FXR deficiency in mice on intestinal cell proliferation and cancer development.
  • The results showed that FXR deficiency resulted in increased colon cell proliferation, which was accompanied by an up-regulation in the expression of genes involved in cell cycle progression and inflammation, including cyclin D1 and interleukin-6.
  • Most importantly, FXR deficiency led to an increase in the size of small intestine adenocarcinomas in adenomatous polyposis coli mutant mice.
  • Furthermore, after treatment with a colon carcinogen, azoxymethane, FXR deficiency increased the adenocarcinoma multiplicity and size in colon and rectum of C57BL/6 mice.
  • Taken together, the current study is the first to show that FXR deficiency promotes cell proliferation, inflammation, and tumorigenesis in the intestine, suggesting that activation of FXR by nonbile acid ligands may protect against intestinal carcinogenesis.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell. 2004 Aug 27;15(4):499-509 [15327767.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):318-25 [17210713.001]
  • [Cites] Digestion. 1974;11(3-4):289-306 [4141314.001]
  • [Cites] J Natl Cancer Inst. 1975 Feb;54(2):439-42 [1113326.001]
  • [Cites] Cancer Res. 1975 May;35(5):1369-71 [1120317.001]
  • [Cites] Prog Clin Biol Res. 1985;186:161-73 [4034597.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cell. 1995 Jun 2;81(5):687-93 [7774010.001]
  • [Cites] Toxicol Pathol. 1996 Nov-Dec;24(6):681-9 [8994294.001]
  • [Cites] Curr Biol. 1997 Jul 1;7(7):R443-6 [9210368.001]
  • [Cites] Carcinogenesis. 1999 Feb;20(2):299-303 [10069468.001]
  • [Cites] Science. 1999 May 21;284(5418):1362-5 [10334992.001]
  • [Cites] Science. 1999 May 21;284(5418):1365-8 [10334993.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6709-18 [16007167.001]
  • [Cites] Cell Metab. 2005 Oct;2(4):217-25 [16213224.001]
  • [Cites] J Lipid Res. 2006 Jan;47(1):201-14 [16251721.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3920-5 [16473946.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):863-7 [17283114.001]
  • [Cites] Carcinogenesis. 2007 May;28(5):940-6 [17183066.001]
  • [Cites] J Med Chem. 2007 May 31;50(11):2622-39 [17489579.001]
  • [Cites] J Lipid Res. 2007 Dec;48(12):2664-72 [17720959.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jan;107(1):49-61 [17333335.001]
  • [Cites] Gastroenterology. 2008 Mar;134(3):793-802 [18325392.001]
  • [Cites] Hepatology. 2008 Jul;48(1):289-98 [18537191.001]
  • [Cites] Mol Cell. 1999 May;3(5):543-53 [10360171.001]
  • [Cites] Cell. 2000 Sep 15;102(6):731-44 [11030617.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1483-92 [11984532.001]
  • [Cites] Med Hypotheses. 2002 Oct;59(4):398-405 [12208178.001]
  • [Cites] Int J Oncol. 2003 Jan;22(1):145-50 [12469197.001]
  • [Cites] J Biol Chem. 2003 Jan 24;278(4):2563-70 [12421815.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):391-400 [12750232.001]
  • [Cites] Mol Biol Cell. 2004 May;15(5):2156-63 [15004225.001]
  • [Cites] J Cell Biochem. 2004 Oct 1;93(2):345-57 [15368361.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10120-6 [17047076.001]
  • [Cites] Mol Cancer. 2006;5:48 [17054793.001]
  • [Cites] Biochim Biophys Acta. 2006 Dec;1761(12):1401-9 [17110163.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):982-9 [15309887.001]
  • (PMID = 18981289.001).
  • [ISSN] 1521-0103
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K12-HD052027; United States / Intramural NIH HHS / / ; United States / NICHD NIH HHS / HD / K12 HD052027; United States / NCRR NIH HHS / RR / P20-RR015563; United States / NCRR NIH HHS / RR / P20-RR021940; United States / NIDDK NIH HHS / DK / R01-DK81343
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Orphan Nuclear Receptors; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Transcription Factors; 0 / farnesoid X-activated receptor; 0 / liver X receptor; MO0N1J0SEN / Azoxymethane
  • [Other-IDs] NLM/ PMC2682273
  •  go-up   go-down


62. Saji H, Kurose K, Sugiura K, Miyagi E, Onose R, Kato H, Nakayama H: Endometrial aspiration cytology for diagnosis of peritoneal lesions in extrauterine malignancies. Acta Cytol; 2007 Jul-Aug;51(4):533-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial aspiration cytology for diagnosis of peritoneal lesions in extrauterine malignancies.
  • OBJECTIVE: To evaluate the usefulness of endometrial aspiration cytology for assessing malignant cells of extrauterine origin.
  • Histologic positive rates were: serous, 28.7%; mucinous, 11.4%; clear cell, 23.1%; endometrioid and unclassifiable adenocarcinomas, 28.0%.
  • In 7 of 17 patients with positive endometrial cytology, clinical diagnosis was made before stomach cancer therapy.
  • CONCLUSION: Endometrial aspiration cytology is useful for identifying nongynecologic malignant cells, diagnosing ovarian and fallopian tube cancers, and determining peritoneal dissemination and metastasis originating from gastrointestinal and breast cancers.
  • [MeSH-major] Endometrium / pathology. Neoplasms / diagnosis. Peritoneum / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17718117.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Suzuki H, Katoh A, Udaka T, Shiomori T, Fujimura T, Fujimura K, Kitamura T: Hyalinizing clear cell carcinoma arising from the base of the tongue. Acta Otolaryngol; 2006 Jun;126(6):653-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyalinizing clear cell carcinoma arising from the base of the tongue.
  • Hyalinizing clear cell carcinoma is a low-grade indolent and rare salivary gland tumor originally described by Milchgrub et al. in 1994.
  • The tumor was histopathologically diagnosed as hyalinizing clear cell carcinoma of the minor salivary gland.
  • The patient is currently free from disease 21 months after surgery.
  • The pathology, clinical characteristics, and treatment of hyalinizing clear cell carcinoma are bibliographically reviewed.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Hyalin. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Laryngoscopy. Magnetic Resonance Imaging. Neck Dissection. Stromal Cells / pathology. Tomography, X-Ray Computed. Tongue / pathology. Tongue / surgery

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720452.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


64. Garg K, Soslow RA: Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma. J Clin Pathol; 2009 Aug;62(8):679-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma.
  • However, there are currently no such screening recommendations for women with endometrial carcinoma.
  • Expansion of these criteria to include tumour morphology (presence of tumour infiltrating lymphocytes and tumour heterogeneity including dedifferentiated/undifferentiated ECs) and topography (lower uterine segment localisation) as well as presence of synchronous ovarian clear cell carcinomas may significantly enhance the detection of patients with EC at risk for HNPCC.
  • [MeSH-major] Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis. Endometrial Neoplasms / diagnosis


65. Elgaaen BV, Haug KB, Wang J, Olstad OK, Fortunati D, Onsrud M, Staff AC, Sauer T, Gautvik KM: POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas. PLoS One; 2010;5(11):e13837
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas.
  • Improved insight into the molecular characteristics of the different subgroups of EOC is urgently needed, and should eventually lead to earlier diagnosis as well as more individualized and effective treatments.
  • Previously, we reported a limited number of mRNAs strongly upregulated in human osteosarcomas and other malignancies, and six were selected to be tested for a possible association with three subgroups of ovarian carcinomas and clinical parameters.
  • METHODOLOGY/PRINCIPAL FINDINGS: The six selected mRNAs were quantified by RT-qPCR in biopsies from eleven poorly differentiated serous carcinomas (PDSC, stage III-IV), twelve moderately differentiated serous carcinomas (MDSC, stage III-IV) and eight clear cell carcinomas (CCC, stage I-IV) of the ovary.
  • The gene expression level was related to the histological and clinical parameters of human ovarian carcinoma samples.
  • Except for POLD2, the serous carcinomas showed a similar transcription profile, being clearly different from CCC.
  • Another mRNA, Killer-specific secretory protein of 37 kDa (KSP37) showed six- to eight-fold higher levels in CCC stage I compared with the more advanced staged carcinomas, and correlated positively with an improved clinical outcome.
  • CONCLUSIONS/SIGNIFICANCE: We have identified two biomarkers which are markedly upregulated in two subgroups of ovarian carcinomas and are also associated with stage and outcome.
  • [MeSH-minor] Aged. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / genetics. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Staging. Neoplasms, Glandular and Epithelial / diagnosis. Neoplasms, Glandular and Epithelial / genetics. Outcome Assessment (Health Care). Ovarian Cysts / diagnosis. Ovarian Cysts / genetics. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Feb;156(2):409-17 [10666369.001]
  • [Cites] JAMA. 2009 Jul 15;302(3):261-75 [19602686.001]
  • [Cites] Mol Cell Biol. 2000 Dec;20(23):9028-40 [11074001.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3741-9 [11325847.001]
  • [Cites] J Immunol. 2001 May 15;166(10):6404-12 [11342666.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):53-62 [12086888.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3B):2201-16 [12894494.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4811-8 [14581352.001]
  • [Cites] BMC Bioinformatics. 2002 Nov 24;3:36 [12445336.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] J Biol Chem. 1987 Mar 25;262(9):4355-9 [3031073.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):669-77 [10091740.001]
  • [Cites] Int Rev Cytol. 2005;242:1-54 [15598466.001]
  • [Cites] FEBS Lett. 2004 Dec 17;578(3):239-44 [15637807.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1053-65 [15558012.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S19-32 [15761464.001]
  • [Cites] J Immunol. 2006 Aug 1;177(3):1772-9 [16849487.001]
  • [Cites] Oncogene. 2006 Sep 28;25(44):5994-6002 [16652150.001]
  • [Cites] Expert Rev Mol Med. 2007;9(13):1-12 [17477890.001]
  • [Cites] J Biomed Inform. 2007 Dec;40(6):707-25 [17418646.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):995-1005 [18195328.001]
  • [Cites] Cell Res. 2008 May;18(5):538-48 [18427574.001]
  • [Cites] Carcinogenesis. 2009 Mar;30(3):423-31 [19126650.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Biochim Biophys Acta. 2000 Sep 7;1493(1-2):231-6 [10978529.001]
  • (PMID = 21079801.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / KSP37 protein, human; 0 / RNA, Messenger; EC 2.7.7.- / DNA Polymerase III; Ovarian epithelial cancer
  • [Other-IDs] NLM/ PMC2973954
  •  go-up   go-down


66. Lauffart B, Vaughan MM, Eddy R, Chervinsky D, DiCioccio RA, Black JD, Still IH: Aberrations of TACC1 and TACC3 are associated with ovarian cancer. BMC Womens Health; 2005 May 26;5:8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The distribution pattern of expression of the two TACC proteins was different, with TACC3 loss being more common in serous papillary carcinoma compared with clear cell carcinomas, while TACC1 staining was less frequent in endometroid than in serous papillary tumor cores.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene Expr Patterns. 2003 May;3(2):203-11 [12711550.001]
  • [Cites] J Histochem Cytochem. 2003 Apr;51(4):455-69 [12642624.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4967-77 [12941822.001]
  • [Cites] Cancer Lett. 2003 Oct 8;200(1):1-7 [14550946.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):29-34 [14668547.001]
  • [Cites] Eur J Cancer. 2004 Jan;40(1):90-5 [14687794.001]
  • [Cites] Curr Biol. 2004 Jan 6;14(1):33-9 [14711411.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):64-71 [14729609.001]
  • [Cites] Oncogene. 2004 Apr 1;23(14):2559-63 [14767476.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23597-605 [15037632.001]
  • [Cites] Br J Haematol. 2004 Jul;126(1):72-6 [15198734.001]
  • [Cites] BMC Evol Biol. 2004 Jun 18;4:16 [15207008.001]
  • [Cites] J Med Genet. 2004 Sep;41(9):e114 [15342711.001]
  • [Cites] Int Rev Cytol. 2004;239:179-272 [15464854.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):767-79 [15705873.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5118-22 [1655245.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] Genes Chromosomes Cancer. 1993 Aug;7(4):219-26 [7692948.001]
  • [Cites] Arch Intern Med. 1995 May 8;155(9):905-12 [7726698.001]
  • [Cites] Cancer. 1995 Oct 15;76(8):1416-21 [8620417.001]
  • [Cites] Br J Cancer. 1996 Dec;74(12):1979-83 [8980400.001]
  • [Cites] Hum Mol Genet. 1998 Feb;7(2):195-202 [9425226.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):893-901 [9486579.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jul;22(3):186-99 [9624530.001]
  • [Cites] Genomics. 1999 Jun 1;58(2):165-70 [10366448.001]
  • [Cites] Oncogene. 1999 Jul 8;18(27):4032-8 [10435627.001]
  • [Cites] Genet Test. 1997-1998;1(3):201-6 [10464646.001]
  • [Cites] Am J Hum Genet. 1999 Oct;65(4):1021-9 [10486320.001]
  • [Cites] Am J Hum Genet. 1999 Dec;65(6):1725-32 [10577927.001]
  • [Cites] Mol Biol Cell. 2000 Apr;11(4):1357-67 [10749935.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4519-25 [10969801.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):90-6 [11006038.001]
  • [Cites] Mech Dev. 2000 Oct;97(1-2):13-26 [11025203.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5382-5 [11034075.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14352-7 [11121038.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Feb;30(2):187-95 [11135436.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):176-80 [11161856.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):1016-24 [11298601.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Feb;33(2):123-32 [11793438.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):171-8 [11812938.001]
  • [Cites] EMBO J. 2002 Feb 15;21(4):653-64 [11847113.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4427-33 [12154050.001]
  • [Cites] Oncogene. 2002 Aug 15;21(36):5619-30 [12165861.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3863-9 [12473601.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):417-23 [12543797.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Nov;139(1):78-83 [12547166.001]
  • [Cites] Genomics. 2003 Feb;81(2):192-201 [12620397.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9 [12714683.001]
  • (PMID = 15918899.001).
  • [ISSN] 1472-6874
  • [Journal-full-title] BMC women's health
  • [ISO-abbreviation] BMC Womens Health
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016056
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1175095
  •  go-up   go-down


67. Mallik AA, Katchy KC: Clear cell adenocarcinoma of the rectum. Med Princ Pract; 2005 Jan-Feb;14(1):58-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the rectum.
  • OBJECTIVE: To document the first case of clear cell adenocarcinoma of the rectum (a rare entity) in Kuwait.
  • Histopathological examination showed the tumor to be composed of lobules of mostly clear polygonal cells with round vesicular nuclei.
  • Glandular formation was occasional.
  • CONCLUSION: This report illustrates a case of intestinal clear cell adenocarcinoma with lymph node metastasis that suggested a poor prognosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15608484.001).
  • [ISSN] 1011-7571
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


68. Girard N, Deshpande C, Lau C, Finley D, Rusch V, Pao W, Travis WD: Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol; 2009 Dec;33(12):1752-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases.
  • The pathologic classification of nonsmall cell lung cancer (NSCLC) is evolving.
  • Lung adenocarcinoma is morphologically heterogeneous, with mixtures of acinar, papillary, bronchioloalveolar, and solid patterns in more than 80% of cases.
  • Genomic and mutational data led to a diagnosis of multiple primaries in 14 cases and of metastases in 8 cases; 2 cases could not be assessed.
  • This molecular characterization contradicted the Martini-Melamed diagnosis in 7 (32%) of the 22 assessable comparisons.
  • Adenocarcinoma was found in 32 (76%) of the 42 tumors.
  • We found that comparing adenocarcinomas is a complex issue that requires assessment not only of percentages of the histologic subtypes, but also the recording of additional histologic details such as cytologic features, patterns of stroma, necrosis, discrete nodularity versus miliary growth and variants such as clear cell, signet ring, mucinous, and fetal patterns.
  • We also found that paired squamous cell carcinomas could be compared based on histologic subtyping in addition to cytologic and stromal characteristics.
  • In summary, based on a well characterized cohort with detailed clinical, pathologic and molecular data, we found comprehensive histologic assessment is a powerful tool that seems to be a promising way to determine whether multiple lung adenocarcinomas or squamous cell carcinomas are metastatic or multiple primaries.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary
  • [MeSH-minor] Cohort Studies. Diagnosis, Differential. Frozen Sections. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Kaplan-Meier Estimate. Mutation. Neoplasm Staging. Predictive Value of Tests. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2008 Jun;32(6):810-27 [18391747.001]
  • [Cites] Ann Thorac Surg. 2003 Oct;76(4):1001-7; discussion 1007-8 [14529975.001]
  • [Cites] J Thorac Cardiovasc Surg. 1975 Oct;70(4):606-12 [170482.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):13-7 [18166835.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):191-202 [8000996.001]
  • [Cites] Eur J Cardiothorac Surg. 2008 Aug;34(2):438-43; discussion 443 [18502660.001]
  • [Cites] Stat Med. 2010 Jul 10;29(15):1608-21 [20205270.001]
  • [Cites] Head Neck. 2002 Feb;24(2):198-206 [11891950.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] J Clin Pathol. 2003 Jul;56(7):522-7 [12835298.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] Clin Cancer Res. 2009 Aug 15;15(16):5184-90 [19671847.001]
  • [Cites] Clin Lung Cancer. 2007 Nov;8(9):562-4 [18186961.001]
  • [Cites] Respirology. 2006 Sep;11(5):533-8 [16916324.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):101-9 [12502932.001]
  • [Cites] Eur Respir J. 2008 Apr;31(4):854-9 [18094005.001]
  • [Cites] Ann Thorac Surg. 2008 Sep;86(3):921-6 [18721583.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 May;133(5):1193-200 [17467428.001]
  • (PMID = 19773638.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / R01 CA124504; United States / NCI NIH HHS / CA / CA124504
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


69. Yi Y, Mikhaylova O, Mamedova A, Bastola P, Biesiada J, Alshaikh E, Levin L, Sheridan RM, Meller J, Czyzyk-Krzeska MF: von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas. Clin Cancer Res; 2010 Nov 1;16(21):5142-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas.
  • PURPOSE: We have previously shown that von Hippel-Lindau (VHL) regulates ubiquitylation and proline 1465 hydroxylation of the large subunit of RNA polymerase II, Rpb1, in human renal clear cell carcinoma (RCC) cell lines.
  • Mechanistic analysis was performed in orthotopic xenograft model using 786-O RCC cells with wild-type (WT) VHL and knockdown of PHD2, characterized by high levels of Rpb1(OH) and PHD1.
  • Knockdown of PHD2 in 786-O VHL(+) cells resulted in a more malignant phenotype in orthotopic xenografts and higher expression of specific cell cycle regulators (CDC25A, cyclin-dependent kinase 2, CCNA2) compared with VHL(-) RCC cells.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Cancer Cell. 2002 Apr;1(3):237-46 [12086860.001]
  • [Cites] Br J Cancer. 2009 Oct 20;101(8):1417-24 [19755989.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1569-75 [12381710.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):75-88 [12559177.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2706-11 [12604794.001]
  • [Cites] PLoS Biol. 2003 Dec;1(3):E83 [14691554.001]
  • [Cites] Trends Mol Med. 2004 Apr;10(4):146-9 [15162797.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9102-7 [9256442.001]
  • [Cites] J Urol. 1998 Oct;160(4):1248-54 [9751329.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(11):4565-78 [15899860.001]
  • [Cites] Urology. 2005 Jun;65(6):1090-5 [15893810.001]
  • [Cites] BMC Cancer. 2005;5:57 [15932632.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2000-11 [16488999.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18154-9 [17114296.001]
  • [Cites] Biochem J. 2007 Jan 1;401(1):217-26 [16958618.001]
  • [Cites] Nat Rev Cancer. 2007 Jul;7(7):495-507 [17568790.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(8):2701-17 [18285459.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):395-400 [18464292.001]
  • [Cites] Cancer Cell. 2008 Dec 9;14(6):435-46 [19061835.001]
  • [Cites] Nat Rev Drug Discov. 2009 Feb;8(2):139-52 [19165233.001]
  • [Cites] Neuroscience. 2009 Feb 18;158(4):1436-45 [19095046.001]
  • [Cites] Adv Enzyme Regul. 2009;49(1):121-32 [19159641.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):673-82 [12209156.001]
  • (PMID = 20978146.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NCI NIH HHS / CA / R01 CA122346; United States / NCI NIH HHS / CA / CA122346; United States / NIEHS NIH HHS / ES / P30-ES006096
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; EC 1.13.11.- / Dioxygenases; EC 1.14.11.2 / EGLN1 protein, human; EC 1.14.11.2 / Procollagen-Proline Dioxygenase; EC 1.14.11.29 / EGLN2 protein, human; EC 1.14.11.29 / Hypoxia-Inducible Factor-Proline Dioxygenases; EC 2.7.7.- / RNA Polymerase II; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  • [Other-IDs] NLM/ NIHMS224724; NLM/ PMC2970636
  •  go-up   go-down


70. Pennathur A, Landreneau RJ, Luketich JD: Surgical aspects of the patient with high-grade dysplasia. Semin Thorac Cardiovasc Surg; 2005;17(4):326-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 1975, about three fourths of the esophageal neoplasms were squamous cell carcinomas and the remainder were adenocarcinomas.
  • During the last 2 to 3 decades, this pattern has changed dramatically and the incidence of squamous cell carcinomas has declined while the incidence of adenocarcinomas has increased.
  • The reason for this dramatic increase is not clear, but gastro esophageal reflux disease, obesity and Barrett's esophagus have been identified as risk factors.
  • High grade dysplasia in Barrett's esophagus is a premalignant condition which can progress to invasive adenocarcinoma.
  • In this article, we discuss the natural history of high grade dysplasia (HGD), difficulties in the diagnosis, the incidence of adenocarcinoma in resected specimens and the surgical aspects in the treatment of HGD, including minimally invasive esophagectomy.
  • [MeSH-minor] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Humans. Lymph Node Excision. Lymphatic Metastasis. Minimally Invasive Surgical Procedures. Quality of Life

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16428039.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


71. Allory Y, Matsuoka Y, Bazille C, Christensen EI, Ronco P, Debiec H: The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin Cancer Res; 2005 Feb 1;11(3):1190-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas.
  • PURPOSE: The L1 cell adhesion molecule is overexpressed in many human carcinomas.
  • The objectives of the study were to provide a comprehensive description of L1 distribution in human kidney and to establish the prognostic relevance of L1 expression in renal cell carcinomas (RCC).
  • In renal tumors, L1 was mainly detected in those originating from cells that do not express L1 in the normal kidney [i.e., 33 of 72 clear cell RCC (ccRCC) and 25 of 88 papillary RCC (papRCC)].
  • In these carcinomas, L1 expression was strongly correlated with Ki-67 proliferation index (ccRCC, P = 0.0059; papRCC, P = 0.0039), but only in ccRCC, the presence of L1 was associated with the risk of metastasis (P = 0.0121).
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Neural Cell Adhesion Molecule L1 / genetics

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709188.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Neural Cell Adhesion Molecule L1; 0 / RNA, Messenger; 136601-57-5 / Cyclin D1
  •  go-up   go-down


72. Hayashi T, Miyagawa Y, Tsujimura A, Nonomura N, Minami M, Okuyama A: A case of renal cell carcinoma with multiple lung metastases refractory to interferon-alpha showing complete remission by interleukin-2 monotherapy. Int J Urol; 2006 Jun;13(6):805-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of renal cell carcinoma with multiple lung metastases refractory to interferon-alpha showing complete remission by interleukin-2 monotherapy.
  • We report a case in which a regimen of interleukin-2 (IL-2) achieved pathologically complete remission against renal cell carcinoma with multiple lung metastases.
  • Right radical nephrectomy was performed and the histological diagnosis was clear cell carcinoma, G3 > G2, INFbeta, pT3a, pN0.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Renal Cell / therapy. Interleukin-2 / administration & dosage. Kidney Neoplasms / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / radiography. Adenocarcinoma, Clear Cell / therapy. Combined Modality Therapy / methods. Humans. Interferon-alpha / administration & dosage. Middle Aged. Neoplasm Metastasis. Nephrectomy / methods. Remission Induction / methods

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16834666.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2
  •  go-up   go-down


73. Tedeschi CA, Rubin M, Krumholz BA: Six cases of women with diethylstilbestrol in utero demonstrating long-term manifestations and current evaluation guidelines. J Low Genit Tract Dis; 2005 Jan;9(1):11-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the late 1960s, an association was made with an increased incidence of clear cell adenocarcinoma in young women exposed in utero to DES.
  • The Centers for Disease Control have conducted a large DES Education Project and have established guidelines for management.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / chemically induced. Adult. Cervical Intraepithelial Neoplasia / chemically induced. Female. Humans. Middle Aged. Pregnancy. Pregnancy Complications / chemically induced. Pregnancy, Ectopic / chemically induced. Time Factors. Uterine Cervical Neoplasms / chemically induced. Vaginal Neoplasms / chemically induced

  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870516.001).
  • [ISSN] 1089-2591
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


74. Signorelli M, Guerra L, Buda A, Picchio M, Mangili G, Dell'Anna T, Sironi S, Messa C: Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: detection of pelvic nodal metastases. Gynecol Oncol; 2009 Nov;115(2):231-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: High risk clinical stage I endometrial cancer (grade 2 and deep myometrial invasion, grade 3 and serous and clear-cell carcinoma) had 10-35% of nodal involvement.
  • Diagnostic performance of 18F-FDG PET/CT in nodal disease detection was reported in terms of accuracy value both in a patient-based and a lesion site-based analysis.
  • Patient-based sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 18F-FDG PET/CT for detection of nodal disease were 77.8%, 100.0%, 100.0%, 93.1% and 94.4%, respectively.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19695685.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


75. Klingler DW, Hemstreet GP, Balaji KC: Feasibility of robotic radical nephrectomy--initial results of single-institution pilot study. Urology; 2005 Jun;65(6):1086-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The final pathologic examination revealed conventional clear cell carcinoma in 4 patients (1 with pT1a, 2 with pT1b, and 1 with T3a) and a benign cyst in 1 patient.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913733.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Kashiwada T, Shimizu H, Arai Y, Horie Y, Mizoo A, Takizawa S: [A case of anaphylactic reaction after pleurodesis with OK-432]. Nihon Kokyuki Gakkai Zasshi; 2009 Oct;47(10):965-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 60-year-old woman had received adjuvant chemotherapy after abdominal hysterectomy for clear cell carcinoma of the endometrium.
  • She underwent drainage of left-side malignant pleural effusion followed by chemical pleurodesis with OK-432 via a chest tube.

  • MedlinePlus Health Information. consumer health - Anaphylaxis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19882924.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 39325-01-4 / Picibanil
  •  go-up   go-down


77. Sakura M, Masuda H, Saito K, Koga F, Kawakami S, Kihara K: Collecting duct carcinoma with acquired cystic disease of the kidney in a long-term hemodialysis patient. Int J Urol; 2008 Jan;15(1):93-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collecting duct carcinoma with acquired cystic disease of the kidney in a long-term hemodialysis patient.
  • We report a very rare case of collecting or Bellini duct carcinoma (CDC) found in a 60-year-old male who had received hemodialysis therapy for 21 years.
  • Screening with ultrasonography revealed a solid tumor originating from the cyst wall in the right kidney with acquired cystic disease of the kidney.
  • The tumor detected preoperatively was composed of papillary renal cell tumor (RCC) and multiple clear cell carcinoma, pathologically.
  • The histological diagnosis was multiple clear cell carcinomas.
  • [MeSH-major] Carcinoma, Renal Cell / etiology. Kidney Diseases, Cystic / etiology. Kidney Neoplasms / etiology. Renal Dialysis / adverse effects


78. Wang ZM, Pan Y, Yao Q, Ying LX: [Hyalinizing clear cell carcinoma]. Zhonghua Bing Li Xue Za Zhi; 2005 Jun;34(6):379-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hyalinizing clear cell carcinoma].
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Palatal Neoplasms / pathology. Tongue Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Keratins / metabolism. Male. Mucin-1 / metabolism. Palate, Hard / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185516.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mucin-1; 68238-35-7 / Keratins
  •  go-up   go-down


79. Wang J, Wieslander C, Hansen G, Cass I, Vasilev S, Holschneider CH: Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers. Gynecol Oncol; 2006 Apr;101(1):120-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers.
  • OBJECTIVE: The objective of this study was to determine the ultrasonographic characteristics of the uterus and endometrial echo-complex (EEC) of postmenopausal patients diagnosed with type 2 endometrial cancer, including uterine papillary serous carcinoma (UPSC), clear cell carcinoma (CCC), and other endometrial high-grade carcinomas (HGC).
  • METHODS: Postmenopausal patients with type 2 endometrial cancer who underwent preoperative pelvic ultrasound were identified.
  • CONCLUSION: A thin or indistinct endometrial stripe, especially when associated with other ultrasound abnormalities does not reliably exclude type 2 endometrial cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16307792.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


80. Wadhwa S, Wadhwa P, Dinda AK, Gupta NP: Differential expression of potassium ion channels in human renal cell carcinoma. Int Urol Nephrol; 2009;41(2):251-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of potassium ion channels in human renal cell carcinoma.
  • We investigate and compare the pattern of expression of EAG and human ERG (HERG) channels in renal cell carcinoma and "normal" renal tissue.
  • Pattern of expression of EAG/HERG channels in normal renal tissue and carcinoma were noted and compared.
  • All tumors in the cohort were clear cell renal carcinoma.
  • Clear cell RCC demonstrated a loss of HERG expression while diffuse overexpression of EAG1 and EAG2 was noted.
  • CONCLUSIONS: In our study both EAG1 and EAG2 potassium channels were overexpressed in clear cell renal cancer.
  • In contrast to other adenocarcinomas, there is loss of HERG expression in clear cell RCC, which may possibly explain its chemoresistance.
  • [MeSH-major] Carcinoma, Renal Cell / metabolism. Ether-A-Go-Go Potassium Channels / metabolism. Kidney Neoplasms / metabolism

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1999 Oct 15;18(20):5540-7 [10523298.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12 ):1722-9 [11104572.001]
  • [Cites] Nature. 2002 Sep 5;419(6902):35-42 [12214225.001]
  • [Cites] FEBS Lett. 2002 Jul 31;524(1-3):204-10 [12135768.001]
  • [Cites] Cancer Lett. 2002 Dec 1;186(1):99-105 [12183081.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17 ):4843-8 [12208728.001]
  • [Cites] Am J Physiol Renal Physiol. 2001 May;280(5):F739-47 [11292615.001]
  • [Cites] J Membr Biol. 2002 Jul 15;188(2):137-49 [12172639.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1791-8 [12200695.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13673-81 [11834728.001]
  • [Cites] Mol Cancer. 2006 Oct 05;5:41 [17022810.001]
  • [Cites] Oncol Rep. 2002 Sep-Oct;9(5):961-4 [12168055.001]
  • [Cites] J Membr Biol. 1996 Nov;154(2):91-107 [8929284.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6996-7001 [15466192.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Aug;56(2):212-20 [15812674.001]
  • [Cites] J Physiol. 1998 Apr 1;508 ( Pt 1):49-56 [9490815.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10036-40 [8234253.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):815-22 [9485040.001]
  • (PMID = 18777199.001).
  • [ISSN] 1573-2584
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / ERG1 Potassium Channel; 0 / Ether-A-Go-Go Potassium Channels; 0 / KCNH1 protein, human; 0 / KCNH2 protein, human; 0 / KCNH6 protein, human
  •  go-up   go-down


81. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR: Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell; 2007 Apr;11(4):321-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
  • One histologic subtype of ovarian carcinoma, ovarian endometrioid adenocarcinoma (OEA), frequently harbors mutations that constitutively activate Wnt/beta-catenin-dependent signaling.
  • Deregulation of these two pathways in the murine ovarian surface epithelium by conditional inactivation of the Pten and Apc tumor suppressor genes results in the formation of adenocarcinomas morphologically similar to human OEAs with 100% penetrance, short latency, and rapid progression to metastatic disease in upwards of 75% of mice.
  • [MeSH-major] Disease Models, Animal. Ovarian Neoplasms / genetics. PTEN Phosphohydrolase / genetics. Phosphatidylinositol 3-Kinases / genetics. Signal Transduction. Wnt1 Protein / genetics. beta Catenin / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenomatous Polyposis Coli Protein / genetics. Adenomatous Polyposis Coli Protein / physiology. Animals. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Epithelium / metabolism. Epithelium / pathology. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Mice. Mutation. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Ovary / metabolism. Ovary / pathology. Survival Rate. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism


82. Gamzatova Z, Villabona L, Dahlgren L, Dalianis T, Nillson B, Bergfeldt K, Masucci GV: Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol; 2006 Oct;103(1):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 44% were serous adenocarcinomas, 28% endometrioid, 6% mucinous, 13% clear cell carcinomas, 7% undifferentiated and 2% other epithelial tumors.
  • CONCLUSIONS: HLA-A2 is a negative factor for survival in women with serous adenocarcinomas of the ovary in stages III-IV.
  • This finding has implications for clinical patient management.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / immunology. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / immunology. Cystadenocarcinoma, Serous / pathology. Female. Humans. Middle Aged. Neoplasm Staging. Paraffin Embedding. Polymerase Chain Reaction. Prognosis. Proportional Hazards Models. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16542716.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HLA-A2 Antigen
  •  go-up   go-down


83. Young RH: From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Adv Anat Pathol; 2007 May;14(3):149-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first tumor discussed is gastric carcinoma of intestinal-type whose ovarian manifestations have been the subject of a recent paper which emphasized its differences from the Krukenberg tumor.
  • Coverage of intestinal adenocarcinoma emphasizes the landmark 1987 paper of RH Lash and WR Hart.
  • The section on pancreatic neoplasms reemphasizes the problems caused by metastatic ductal carcinoma, considered primarily in Part I, and discusses less common issues such as spread of neuroendocrine and acinar cell carcinomas.
  • The limited information on spread of tumors of the gallbladder and extrahepatic bile ducts is then reviewed before more detailed consideration of hepatic neoplasms, prompted by recent contributions on hepatocellular carcinoma and intrahepatic cholangiocarcinoma, the latter based on significant experience with this problem in Thailand.
  • The section on appendiceal neoplasms highlights ovarian spread of diverse tumors ranging from typical intestinal-type adenocarcinoma to signet-ring cell carcinomas with various patterns which in the ovary may prompt diagnoses such as a goblet cell (mucinous) carcinoid tumor, but whose ovarian features place them in the category of a Krukenberg tumor.
  • The diverse problems in differential diagnosis of carcinoid tumor (provoked by nested, acinar, and other patterns, including folliclelike spaces) are then reviewed.
  • The section on breast cancer emphasizes that, although usually a manifestation of late stage disease and often not bulky in the ovaries, metastatic breast cancer may form large masses which can represent the clinical presentation.
  • The section on lung tumors largely reflects information in a recent paper that small cell carcinoma and adenocarcinoma are the lung cancers that spread to the ovary most commonly.
  • The extremely broad differential diagnosis posed by metastatic malignant melanoma ranging from that of an oxyphilic tumor, to a small cell tumor, to a follicle-forming neoplasm, is then considered.
  • The sections on renal cell carcinoma and other urinary tract neoplasms emphasize the differential diagnosis of metastatic clear cell carcinoma and primary clear cell carcinoma, an issue usually resolvable by an awareness of the various features of the ovarian variant, rarely or never seen in the renal variant.
  • The sections on ovarian spread of uterine carcinomas emphasize the problems owing to cervical adenocarcinomas, which have a greater tendency to involve the ovaries than squamous cell carcinomas and can simulate primary mucinous or endometrioid cancers.
  • The final neoplasms considered are malignant mesothelioma and the desmoplastic small round cell tumor.
  • The microscopic features of malignant mesothelioma are so different from those of primary ovarian carcinoma in most instances that the diagnosis should be readily established on routine microscopic evaluation.
  • The differential diagnosis of the desmoplastic small round cell tumor is more complex because of the greater overlap with the many other small cell malignant tumors that may involve the ovaries primarily or secondarily.
  • However, as pointed out in brief concluding remarks, despite the aid of that modality, as in surgical pathology overall, careful consideration of the clinical background, distribution of disease, gross characteristics and spectrum of routine microscopic findings, will lead to the correct diagnosis in the majority of cases and at the very least lead to formulation of a considered differential diagnosis such that use of special techniques may be judicious and those results placed in context of the time-honored clinical and pathologic features.
  • [MeSH-major] Carcinoma / secondary. Krukenberg Tumor / secondary. Ovarian Neoplasms / secondary
  • [MeSH-minor] Diagnosis, Differential. Female. History, 19th Century. History, 20th Century. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17452813.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  •  go-up   go-down


84. Bagby CM, MacLennan GT: Clear cell adenocarcinoma of the bladder and urethra. J Urol; 2008 Dec;180(6):2656
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the bladder and urethra.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Urethral Neoplasms / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18951583.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Tajiri K, Shimizu Y, Mihara H, Kawanishi Y, Orihara T, Takahashi H, Ishizawa S, Kawai S, Sugiyama T: Cholangiocarcinoma at the cystic duct discovered by lymph node metastases with clear cell transformation. Intern Med; 2006;45(18):1045-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholangiocarcinoma at the cystic duct discovered by lymph node metastases with clear cell transformation.
  • We encountered a case with cholangiocarcinoma of the cystic duct, which was first manifested by multiple lymph node metastases with clear cell changes resembling clear cell adenocarcinoma (CCC).
  • Because the clear cell changes were not prominent at the primary site, clear cell transformation might have occurred preferentially at the metastatic lesion in this case.
  • Alternatively, tumor cells with clear cell transformation, found at the primary site, might have high metastatic potential.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Bile Duct Neoplasms / pathology. Cholangiocarcinoma / pathology. Cystic Duct

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Intern Med. 2006;45(18):1025-6 [17043371.001]
  • (PMID = 17043375.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


86. Delahunt B, Bethwaite PB, McCredie MR, Nacey JN: The evolution of collagen expression in sarcomatoid renal cell carcinoma. Hum Pathol; 2007 Sep;38(9):1372-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The evolution of collagen expression in sarcomatoid renal cell carcinoma.
  • The development of a sarcomatoid morphotype is recognized as an extreme form of dedifferentiation in renal cell carcinoma and is associated with a poor prognosis.
  • Although sarcomatoid renal cell carcinoma shows pronounced spindle cell morphology, clear cell renal cell carcinoma may show early spindle cell change with cellular elongation, and the prognostic significance of this is debated.
  • To determine the relationship between sarcomatoid renal cell carcinoma and clear cell renal cell carcinoma showing early spindle cell change, we have investigated collagen expression using immunohistochemistry in these 2 tumor types.
  • Both sarcomatoid renal cell carcinoma and early spindle cell change tumors showed pericellular interstitial expression of collagen types I and III, whereas sarcomatoid renal cell carcinoma also showed cytoplasmic expression of these collagen types.
  • Expression of these collagen types in typical clear cell renal cell carcinoma was, in occasional cases, limited to faint and patchy staining in a pericellular interstitial distribution.
  • Tumor cells did not stain for collagen type IV in sarcomatoid renal cell carcinoma, early spindle cell change, or typical clear cell renal cell carcinoma.
  • In sarcomatoid renal cell carcinoma, there was diffuse pericellular expression of collagen type V and patchy pericellular expression of collagen type VI, whereas early spindle cell change tumors showed patchy pericellular staining with antibodies to collagen type V.
  • Collagen type VI expression in early spindle cell change was largely confined to the vascular adventitia and areas of scarring, although very occasional foci of faint interstitial staining were also seen.
  • In typical clear cell renal cell carcinoma, staining of collagen types V and VI was limited to the vascular adventitia and foci of desmoplasia, whereas no staining of tumor cell cytoplasm were seen.
  • This study has shown that collagen expression of sarcomatoid renal cell carcinoma differs from that of early spindle cell change and provides validating evidence that these 2 morphotypes should not be considered together for classification purposes.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Collagen / analysis. Kidney Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Collagen Type I / analysis. Collagen Type III / analysis. Collagen Type IV / analysis. Collagen Type V / analysis. Collagen Type VI / analysis. Cytoplasm / chemistry. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17521699.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Collagen Type III; 0 / Collagen Type IV; 0 / Collagen Type V; 0 / Collagen Type VI; 9007-34-5 / Collagen
  •  go-up   go-down


87. Reichelt O, Gajda M, Chyhrai A, Wunderlich H, Junker K, Schubert J: Ultrasound-guided biopsy of homogenous solid renal masses. Eur Urol; 2007 Nov;52(5):1421-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Morphologic characteristics seen on ultrasound were categorized in (non-)homogenous and (non-)cystic renal masses and were related to findings of pathological examination.
  • RESULTS: In the ultrasound study, only 16 (22.9%) of the 76 clear-cell carcinomas but all 9 (100%) oncocytoma appeared homogenous and noncystic on high-resolution intraoperative ultrasound.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Nephrectomy / methods. Prospective Studies. Reproducibility of Results


88. Houghton O, Connolly LE, McCluggage WG: Morules in endometrioid proliferations of the uterus and ovary consistently express the intestinal transcription factor CDX2. Histopathology; 2008 Aug;53(2):156-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: Cases of uterine or ovarian endometrioid glandular lesions with squamous elements were stained with CDX2, beta-catenin, oestrogen receptor (ER), CD10, p63 and high-molecular-weight cytokeratin LP34.
  • Ten endometrioid carcinomas not exhibiting squamous differentiation were immunoreactive for CDX2; one was focally positive.
  • Electron microscopy in two ovarian endometrioid adenocarcinomas with extensive morular differentiation showed that the morules exhibited epithelial features, but no overt evidence of squamous differentiation.
  • Nuclear beta-catenin positivity is in keeping with the observation that endometrioid glandular lesions with morules are often associated with beta-catenin gene mutation.
  • The explanation for diffuse nuclear positivity with the intestinal transcription factor CDX2 in morules is not clear, but may be a result of overexpression of nuclear beta-catenin.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Cell Proliferation. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Homeodomain Proteins / genetics. Intestines / metabolism. Ovarian Neoplasms / metabolism. Ovary / metabolism
  • [MeSH-minor] Cell Nucleus / metabolism. Female. Humans. Prospective Studies. beta Catenin / biosynthesis. beta Catenin / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2009 Mar;54(4):495-7 [19309406.001]
  • (PMID = 18752499.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Homeodomain Proteins; 0 / beta Catenin
  •  go-up   go-down


89. Cao D, Guo S, Allan RW, Molberg KH, Peng Y: SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma. Am J Surg Pathol; 2009 Jun;33(6):894-904
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma.
  • Ovarian primitive germ cell tumors (GCTs) are uncommon tumors and sometimes pose diagnostic challenges.
  • Among them, yolk sac tumor (YST) poses the greatest diagnostic difficulty and can be mistaken for clear cell carcinoma (CCC).
  • Here by immunohistochemistry, we investigated a novel marker SALL4 in 98 GCTs (29 YSTs, 18 dysgerminomas, 6 gonadoblastomas, 6 embryonal carcinomas, 15 immature and 12 mature teratomas, 7 carcinoid tumors, 3 strumal carcinoids, and 2 struma ovarii) with particular interest of exploring SALL4 to distinguish YST from CCC.
  • We found that SALL4 is strongly positive in more than 90% tumor cells in all YSTs, dysgerminomas, gonadoblastomas, and embryonal carcinomas.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Endodermal Sinus Tumor / diagnosis. Ovarian Neoplasms / diagnosis. Transcription Factors / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / metabolism. Sensitivity and Specificity


90. Hou TC, Wu CC, Yang CR, Wang J: Synchronous renal cell carcinoma and clear cell hepatocellular carcinoma mimicking metastatic disease. Pathol Res Pract; 2010 May 15;206(5):342-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous renal cell carcinoma and clear cell hepatocellular carcinoma mimicking metastatic disease.
  • Double carcinomas of hepatocellular and renal cell carcinoma (RCC) are extremely rare, and among the reported cases, none of the hepatocellular carcinomas show clear cell change.
  • We report a case of synchronous double primary clear cell tumor in the liver and the kidney of a 70-year-old male.
  • The renal mass was a renal cell carcinoma of mixed clear and granular cell types, and the hepatic mass was a hepatocellular carcinoma with extensive clear cell change that mimicked a metastatic renal cell carcinoma.
  • A simple battery of immunohistochemical stains composed of hepatocyte antigen, and CD10 was performed to make a definite diagnosis.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Liver Neoplasms / pathology. Neoplasm Metastasis / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male


91. Chen CH, Shen J, Lee WJ, Chow SN: Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer. Int J Gynecol Cancer; 2005 Sep-Oct;15(5):878-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyclin D1 and c-Myc are key participants in the cell-cycle pathway, in which aberrancies have been associated with malignant transformation.
  • Immunohistochemical analysis was performed on 12 normal ovaries and 47 cases of serous, mucinous, endometrioid, and clear cell ovarian carcinomas.
  • There was no significant difference of overexpression of cyclin D1 or c-Myc gene products between these four histologic subtypes of ovarian adenocarcinomas.
  • This study shows that cyclin D1 and c-Myc are frequently overexpressed in epithelial ovarian carcinomas, but they are not correlated with a particular histologic subtype.


92. Bukowski RM: Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach. Expert Opin Pharmacother; 2010 Oct;11(14):2351-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
  • Over 13,000 patients are estimated to die from this disease annually.
  • Cloning of the VHL gene, recognition of the associated abnormalities in sporadic clear-cell carcinoma, and its role as a regulator of the hypoxic response, were important milestones in our understanding of renal-cell carcinoma (RCC) biology and the recognition of the vascular endothelial growth factor (VEGF) dependency of RCC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20586712.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 0 / Protein Kinase Inhibitors; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


93. Stylianou S, Clarke RB, Brennan K: Aberrant activation of notch signaling in human breast cancer. Cancer Res; 2006 Feb 1;66(3):1517-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A role for Notch signaling in human breast cancer has been suggested by both the development of adenocarcinomas in the murine mammary gland following pathway activation and the loss of Numb expression, a negative regulator of the Notch pathway, in a large proportion of breast carcinomas.
  • However, it is not clear currently whether Notch signaling is frequently activated in breast tumors, and how it causes cellular transformation.
  • Here, we show accumulation of the intracellular domain of Notch1 and hence increased Notch signaling in a wide variety of human breast carcinomas.
  • More significantly, we show that attenuation of Notch signaling reverts the transformed phenotype of human breast cancer cell lines, suggesting that inhibition of Notch signaling may be a therapeutic strategy for this disease.
  • [MeSH-minor] Apoptosis / physiology. Cell Line, Tumor. Cell Transformation, Neoplastic / metabolism. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Receptors, Notch / metabolism. Signal Transduction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452208.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; 0 / Receptors, Notch
  •  go-up   go-down


94. Yamashita R, Yamaguchi R, Yuen K, Niwakawa M, Tobisu K: Urothelial carcinoma (clear cell variant) diagnosed with useful immunohistochemistry stain. Int J Urol; 2006 Nov;13(11):1448-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urothelial carcinoma (clear cell variant) diagnosed with useful immunohistochemistry stain.
  • The case is reported of urothelial carcinoma (clear cell variant) that was diagnosed with useful immunohistochemistry stain.
  • A 70-year-old man, who had undergone left radical nephrectomy for renal cell carcinoma in August 2003 and partial lobectomy for pulmonary metastasis in May 2005, complained of hematuria in June 2005.
  • The pathological diagnosis was difficult due to diffuse clear cell appearance.
  • Immunohistochemistry stain showed urothelial carcinoma, not metastasis of the renal cell carcinoma.
  • Finally it was diagnosed as urothelial carcinoma clear cell variant.
  • Urothelial carcinoma has many variants that show a variety of appearances and characteristics.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Immunohistochemistry / methods. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Keratin-7 / analysis. Male. Reproducibility of Results. Sensitivity and Specificity. Urothelium / chemistry. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083402.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Keratin-7
  •  go-up   go-down


95. Jin JS, Yao CW, Loh SH, Cheng MF, Hsieh DS, Bai CY: Increasing expression of extracellular matrix metalloprotease inducer in ovary tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Gynecol Pathol; 2006 Apr;25(2):140-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Invasion is largely mediated by matrix metalloproteases that are thought to be induced by tumor cell-derived extracellular matrix metalloprotease inducer (EMMPRIN) in surrounding fibroblasts.
  • Immunohistochemical analysis of EMMPRIN was performed in tissue microarrays of ovary neoplasms including 84 cases of serous adenocarcinoma, 23 cases of mucinous adenocarcinoma, 10 cases of endometrioid adenocarcinoma, 12 cases of yolk sac tumor, 12 cases of clear cell carcinoma, 8 cases of dysgerminoma, 8 cases of granulosa cell tumor, 6 cases of transitional cell carcinoma, and 6 cases of Brenner tumor.
  • All malignant ovary tumors showed significant immunohistochemical expression of EMMPRIN.
  • The EMMPRIN scores in malignant ovary tumors were significantly higher than their nontumor counterparts (313+/-28 for serous adenocarcinoma; 308+/-25 for mucinous adenocarcinoma; 187+/-19 for endometrioid adenocarcinoma; 265+/-23 for yolk sac tumors; 87+/-13 for clear cellcarcinoma; 126+/-15 for dysgerminoma; 243+/-26 for granulosa cell tumor; 87+/-16 for transitional cell carcinoma).
  • The EMMPRIN score was significantly higher in serous adenocarcinomas than in serous adenomas and serous borderline tumors and was correlated with nodal stage.
  • Our findings show for the first time that EMMPRIN is overexpressed in all malignant ovary tumors.
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma, Clear Cell / chemistry. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Brenner Tumor / chemistry. Brenner Tumor / genetics. Brenner Tumor / pathology. Carcinoma, Transitional Cell / chemistry. Carcinoma, Transitional Cell / genetics. Carcinoma, Transitional Cell / pathology. Dysgerminoma / chemistry. Dysgerminoma / genetics. Dysgerminoma / pathology. Endodermal Sinus Tumor / chemistry. Endodermal Sinus Tumor / genetics. Endodermal Sinus Tumor / pathology. Female. Granulosa Cell Tumor / chemistry. Granulosa Cell Tumor / genetics. Granulosa Cell Tumor / pathology. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633062.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 136894-56-9 / Antigens, CD147
  •  go-up   go-down


96. Coosemans A, Moerman P, Verbist G, Maes W, Neven P, Vergote I, Van Gool SW, Amant F: Wilms' tumor gene 1 (WT1) in endometrial carcinoma. Gynecol Oncol; 2008 Dec;111(3):502-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor gene 1 (WT1) in endometrial carcinoma.
  • To expand the knowledge on the biological role of WT1 in other uterine cancers, we focused on its detection in endometrial carcinoma.
  • METHODS: In total, 36 paraffin-embedded tumors were available for WT1 immunohistochemical (IHC) analysis including endometrial endometrioid carcinoma (n=24), serous carcinoma (n=9) and clear cell carcinoma (n=3).
  • Of these tumors, 32 snap frozen tissue samples were available for RT-PCR (endometrioid carcinoma (23), serous carcinoma (7) and clear cell carcinoma (2)).
  • CONCLUSION: Although WT1 is expressed in a majority of endometrial carcinomas, a heterogeneous staining pattern is observed.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Aged. Biopsy. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Female. Humans. Immunohistochemistry. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction. WT1 Proteins / biosynthesis. WT1 Proteins / genetics

  • Genetic Alliance. consumer health - Wilms' tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18929401.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / WT1 Proteins
  •  go-up   go-down


97. Uharcek P: Prognostic factors in endometrial carcinoma. J Obstet Gynaecol Res; 2008 Oct;34(5):776-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in endometrial carcinoma.
  • Endometrial carcinoma is the most common malignancy of the female genital tract in industrialized countries, and occurs predominantly after the menopause.
  • Although most endometrial carcinomas are detected at low stage, there is still a significant mortality from the disease.
  • In order to improve treatment and follow-up of endometrial carcinoma patients, the importance of various prognostic factors has been extensively studied.
  • Over the past few decades, several studies have demonstrated the prognostic importance of different parameters including lymph node status, histological type of carcinoma (serous carcinoma and clear cell carcinomas are poor prognostic types), histological grade, stage of disease, depth of myometrial invasion, lymphovascular space involvement and cervical involvement.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology


98. Adams B, Sawhney R, Sheil A, Chaudhary UB: A rare case of clear cell adenocarcinoma of the bladder with unique pathological features. Am J Med Sci; 2007 Jan;333(1):63-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of clear cell adenocarcinoma of the bladder with unique pathological features.
  • Clear cell adenocarcinomas of the urinary bladder are rare tumors with an unknown histogenesis.
  • Since these tumors appear histologically similar to clear cell tumors of the female genital tract, a mullerian histogenesis has been proposed.
  • Several publications have examined the immunohistochemical properties of clear cell adenocarcinomas to improve understanding of the cause and pathogenesis of this tumor.
  • While specific criteria for a diagnosis of clear cell adenocarcinoma have not been defined, there are consistent staining patterns suggested for characterization.
  • We present an important case of clear cell adenocarcinoma of the bladder with a unique staining pattern.
  • We review the literature and discuss the differential diagnosis and various theories concerning the origin of this rare tumor.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17220697.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


99. Fujiu K, Miyamoto H, Hashimoto S, Suzuki N, Takano Y, Teranishi Y, Sakuma H, Suzuki H: A case of diaphragmatic clear cell carcinoma in a patient with a medical history of ovarian endometriosis. Int J Clin Oncol; 2010 Oct;15(5):489-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of diaphragmatic clear cell carcinoma in a patient with a medical history of ovarian endometriosis.
  • We present a case of clear cell carcinoma located in the diaphragm in a patient with a medical history of ovarian endometriosis.
  • Histopathological examination revealed the presence of clear cells and hobnail cells.
  • The clear cells contained pale or eosinophilic cytoplasm and were arranged in a solid pattern.
  • The findings were compatible with those of ovarian clear cell carcinoma.

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1980 Mar 1;45(5):943-7 [7260845.001]
  • [Cites] Ann R Coll Surg Engl. 2006 Oct;88(6):547-9 [17059714.001]
  • [Cites] Gynecol Oncol. 1991 Jun;41(3):259-62 [1714418.001]
  • [Cites] Tohoku J Exp Med. 2005 Jul;206(3):271-5 [15942157.001]
  • [Cites] Obstet Gynecol. 1990 Jun;75(6):1023-8 [2188180.001]
  • (PMID = 20221659.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


100. Nagase S, Katabuchi H, Hiura M, Sakuragi N, Aoki Y, Kigawa J, Saito T, Hachisuga T, Ito K, Uno T, Katsumata N, Komiyama S, Susumu N, Emoto M, Kobayashi H, Metoki H, Konishi I, Ochiai K, Mikami M, Sugiyama T, Mukai M, Sagae S, Hoshiai H, Aoki D, Ohmichi M, Yoshikawa H, Iwasaka T, Udagawa Y, Yaegashi N, Japan Society of Gynecologic Oncology: Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition. Int J Clin Oncol; 2010 Dec;15(6):531-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrial carcinoma is one of the most common gynecologic malignancies in Japan and its incidence has increased recently.
  • Although surgery is the cornerstone of the management of patients with endometrial cancer, there is significant variation in Japan with regard to the type of hysterectomy employed.
  • The 2009 edition included topics not addressed in the previous edition including the treatment of mesenchymal tumors, for example leiomyosarcoma, and sections covering the treatment of serous and clear-cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / therapy. Endometrial Neoplasms / therapy. Uterine Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2009 Jan 10;373(9658):125-36 [19070889.001]
  • [Cites] J Natl Compr Canc Netw. 2009 Oct;7(9):908-42 [19878637.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):325-8 [17267025.001]
  • [Cites] Jpn J Clin Oncol. 2009 Dec;39(12):850-8 [19797417.001]
  • [Cites] Lancet. 2010 Apr 3;375(9721):1165-72 [20188410.001]
  • (PMID = 21069552.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement